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Abstract 
Introduction: In South Africa, neuropsychiatric conditions rank third in its contribution to the 
burden of disease, after AIDS and other infectious diseases.  Within the past two decades, the 
prescribing and subsequent use of antidepressants has become increasingly common, even 
among children and adolescents. Selective serotonin reuptake inhibitors (SSRIs) and tricyclic 
antidepressants (TCAs) are widely prescribed by doctors for depression, panic, anxiety, pain 
and stress disorders. The aim of this study was to conduct a retrospective drug utilisation review 
on the prescribing of antidepressant drugs in a public health sector outpatient psychiatric clinic 
and to calculate the drug cost associated with treating depression in this study. The study was 
conducted on records over a period from January 2011 to September 2014. 
Methods: Following ethical approval for the study, out-patient prescription records are obtained 
from the Charlotte Maxeke Johannesburg Academic hospitals psychiatric clinic. This information 
was then recorded on case report forms and later transferred to a purpose designed spread 
sheet using Microsoft Excel 2010. Descriptive statistics were used to chart the use of specific 
antidepressants, the patient demographics and the indications for antidepressant use. 
Inferential statistics were used to document correlations and drug use. 
Results: The patient population consisted of 41 male (30.30%) and 94 female patients 
(69.70%). The population consisted of various ethnicities of which 35.70% (n=48) were Black, 
10.30% (n=14) were colored, 13.30% (n=18) were Indian and 40.70% (n=55) were White. The 
average age of all the patients was 50.16 years (SD= 16.32). Unemployed patients consisted of 
50.40% of the patient population whilst only 23.70% of patients were employed and the 
remainders were pensioners (25.90%). Married patients consisted of 54.81% of the sample 
whilst single, widowed or divorced patients comprised 45.19%. More than half of the patients 
had been diagnosed with major depressive disorder or MDD (56.30%). Patients who had also 
been receiving treatment for a bipolar mood disorder had also been receiving antidepressant 
therapy (10.37%). Mild depression and MDD with psychotic features were the least present 
diagnosis (0.74% and 4.44% respectively). Of the total patient population, almost half had been 
prescribed citalopram as their antidepressant (51.61%), followed by venlafaxine (30.33%) then 
fluoxetine (18.03%). The patient race has been shown to influence the type of antidepressant 
chosen (p< 0.0001). There were correlations between the antidepressant chosen and patient 
race as well as marital status (p<0.0001). As shown in a number of other studies, there are 
more female patients receiving antidepressant therapy than males. In this study the amount of 
black male and female patients had been nearly equal with white patients having been 
IV 
 
composed of more females than males. For coloured and Indian patients, there had been more 
males than female patients. As expected, the diagnosis of a patient, which had been noted 
using the ICD 10 codes, had a great influence on the type of antidepressant chosen (p<0.000). 
The ICD codes used were for the range of depressive disorders from F32 to F42 (Appendix D).  
.The antidepressant with the most amounts of repeat prescriptions was venlafaxine with an 
average of 15.13 repeats followed by fluoxetine with 11.77 repeats and citalopram with 10.67 
repeats. As shown previously with the total patient population, most males and females had 
been prescribed citalopram, although it had been prescribed to 12.33% more of the female 
patients. Fluoxetine was however prescribed to a slightly greater extent to males than females. 
Fluoxetine was however prescribed to a slightly greater extent to males than females. 
Citalopram had been the preferred antidepressant in Black, Coloured and White patients 
(57.14%; 58.30% and 44.00% respectively). Venlafaxine had been prescribed to a much greater 
extent in the Indian population (55.60%). Fluoxetine had been prescribed more to Black patients 
than other race group with the same group having venlafaxine prescribed to the least amount of 
patients. With employed patients, citalopram had been the most frequently prescribed (52.40%) 
followed by fluoxetine (26.66%) then Venlafaxine (20.94%). In the unemployed group of 
patients, the second most frequently prescribed drug was venlafaxine (26.96%) followed by 
fluoxetine (15.19%). The type of antidepressant chosen was shown to be influenced by the 
marital status of the patient (p= 0.048). The most expensive antidepressant used had been 
venlafaxine with an average cost per patient of R144.12 per month. Fluoxetine had been the 
cheapest antidepressant with only a small difference, of between R1.02 and R3.00, as 
compared to the slightly more expensive citalopram. 
Conclusion: The data correlates with a number of international DURs and has provided valuable 
insight into the use of antidepressants in the public sector. 
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Chapter One: Rationale for this study 
 
The use of antidepressants has increased within the last two decades (Aarts et al, 2014; 
Vetulani and Nalepa 2000; Courtet et al, 2014). As a result of the increased prescribing and use 
of antidepressants, the need for information regarding the actual prescribing practices has 
become vitally important in order to maintain patient safety as well as to ensure that the optimal 
therapeutic outcome is achieved, especially when the nature of the side effects of these drugs 
are considered (Artigas, 2015). Within the past decade, there has been a considerable amount 
of drug utilization reviews on antidepressants that have been conducted as the use of these 
drugs gained the interest of many researchers. The results of these DURs do vary slightly 
however all do provide vital information that can help to improve the prescribing process of 
antidepressants (Bauer et al, 2008; Gondalez et al, 2010; Serna et al, 2010). 
A retrospective DUR involves reviewing therapy after the patient has received treatment. A 
retrospective review may detect patterns in prescribing, dispensing, or administering drugs to 
prevent recurrence of inappropriate use of drugs (Hess, 2004). In this study, patient records 
were reviewed and information such as age, sex, race and area of residence were recorded to 
chart differences in patient demographics. Information about antidepressant drugs as well as 
dose, frequency of dosing and dosing instructions were collated and analysed to infer patterns 
of prescribing of these drugs. 
 
Most of the South African published drug utilisation reviews on antidepressants records that 
were reviewed are from a decade ago and were from a private medical scheme (Truter and 
Kotze 2007, 1997), the results showed a deviation of actual prescribing practices from the 
recommended guidelines. This proposed study differs from the previous DURs in that it will be 
the first to be conducted in the state health facilities. The study results could inform 
antidepressant prescribing in the public sector and contribute to improved patient care.  
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1.1 Aim 
 
The aim of this study was to conduct a drug utilisation review and identify the costs directly 
associated with antidepressant prescribing in an outpatient psychiatric clinic at a Gauteng 
Academic hospital. 
 
 1.2 Study Objectives 
 To determine which antidepressants are prescribed 
 To determine the frequency of antidepressant drugs prescribed as well as their doses 
 To quantify the patient return-rate through repeat prescriptions 
 To investigate whether patient demographics vary with prescribed antidepressant 
  To investigate whether patient diagnosis varies with antidepressant prescribed 
 To compare drug use in the public sector with EDL recommendations and standard 
treatment guidelines (STGs).   
 To calculate the costs associated with antidepressant prescriptions in the out-patient 
clinic. 
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Chapter Two: Literature review 
 
2.1 Retrospective drug utilization reviews 
 
A retrospective review utilizes existing data that have been collected for reasons other than 
research, these data are best represented as prescriptions and patient records (Hess, 2004). A 
retrospective review can find patterns in prescribing, dispensing, or administering drugs, helps 
to prevent occurrence of inappropriate medicine use and serves as a platform for developing 
prospective recommendations and target interventions. In this kind of drug utilization review 
(DUR), patient medical records are analysed to detect whether the drug therapy has met the 
approved criteria and aids prescribers’ in improving care for their patients, individually and within 
groups of patients, such as those with psychiatric disorders.  
One of the most important aspects to measure, when conducting a retrospective review, is the 
amount of drug prescribed which is then compared to a recommended dose. Antidepressant 
medication should be prescribed in the correct doses in order to achieve the desired therapeutic 
effect and avoid toxicity (Truter and Kotze, 2007). A drug utilisation research method that is 
used for the analysis of data is the Defined Daily Dose (DDD) method. DDD is known as the 
dose which corresponds to the average dose per day for a drug, when used for the main 
indication in adults (WHO, 2003). There are limitations to the use of the DDD because a large 
percentage of drugs are used for off –label indications, therefore are used at different dosages. 
The DDD is a technical unit of measurement, and is not necessarily equivalent to the average 
doses actually prescribed. Therefore, the prescribed daily dose (PDD) is used to overcome the 
limitations of the DDD. The PDD is  the actual prescribed dose of the drug and is obtained by 
the dosing instructions in prescriptions  (Truter and Kotze, 1997). By using the dosing 
instructions it is seen how many times per day the drug would be taken, this helps to enable 
calculation of the total daily dose. An example of the use of this method is a study that had been 
conducted in 2000, which focused on a sample of 98 adolescents and young adults in South 
Africa and investigated the prescribing patterns of TCAs and SSRIs, the found that the SSRIs 
were more likely to be prescribed within a close range of the DDD than the TCAs (Kairuz et al, 
2003).  
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2.2. Antidepressant prescribing across various countries 
 
A study by Bauer and other researchers conducted in 2008 aimed at describing the prescribing 
patterns as well as any factors that influence the choice on antidepressant by prescriber in the 
Factors Influencing Depression Endpoints Research (FINDER) study that involved 3468 
patients in 12 European countries. This study had been done as a result of growing curiosity 
among researchers in Europe after it had been shown by surveys that there were differences 
between European countries in the prescribing of antidepressants where TCAs were favored 
more in some countries but SSRIs more frequently prescribed in others (Tylee et al., 1999). This 
variation is evident even though other studies had shown that there had been a shift from the 
prescribing of TCAs (Tricyclic antidepressants) to the better tolerated SSRIs (Selective 
serotonin re-uptake inhibitors) (Guaiana et al, 2005; Lawrenson et al, 2000; Van Marwijk et al, 
2001). FINDER was an observational study that involved 12 European countries namely: 
Austria, Belgium, France, Germany, Ireland, Italy, the Netherlands, Norway, Portugal, Sweden, 
Switzerland and the UK (Garcia- Cebrian et al, 2008). This study had been designed to help 
understand the types of factors that can affect the health-related quality of life (HRQoL) 
outcomes for patients undergoing treatment for depression. This study had been used by the 
researchers to determine the physician and patient characteristics that influence the type of 
antidepressant that will be initially selected (Bauer et al, 2008). All the patients who participated 
in this study were adults over the age of 18.  
 
The results of the study showed that the most commonly prescribed antidepressants were 
SSRIs (63.3% of all patients) followed by SNRIs (Serotonin and noradrenalin re-uptake 
inhibitors) (13.6% of all patients) (Bauer et al., 2008). The prescribing of different antidepressant 
groups varied between countries; SSRIs prescribed ranged from 31.7% in Germany to 81.5% in 
France. TCAs were prescribed for only 1.5% of patients in the Netherlands and 8.6% in Austria 
but accounted for 26.5% of antidepressants prescribed in Germany. Combinations of 
antidepressants were prescribed more frequently in Austria (24. 5% of patients) whilst no 
combinations at all were used in the Netherlands and Ireland. The mean dose of amitriptyline 
(55.6mg/day) is considerably lower than the recommended dose (75mg/day). Interestingly, it 
also had been shown that primary care physicians prescribed higher mean dosed for duloxetine 
and trazodone but lower mean doses for amitriptyline and venlafaxine. 
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 A study in the United States aimed at investigating the utilization, price and spending patterns 
of antidepressants during the period from January 1991 to December 2005 (Chen et al, 2008). 
This study had used information from a Medicaid program in which a descriptive time series had 
been conducted to assess the trends of expenditure, utilization, market shares and prices during 
the specified time for SSRIs, TCAs and other antidepressants. The study had found that during 
the 1990’s, antidepressants were the most widely prescribed medication in the US. The study 
showed that the amount of antidepressant prescriptions had increased drastically from 6.8 
million in 1991 to 35.0 million in 2004 but then decreased to 32.7 million prescriptions in 2005. 
The way in which the prescribing of SSRIs had come to dominate was shown in the study by the 
increase in the number of prescription from 1.0 million in 1991 to 20.8 million in 2005 (Chen et 
al, 2008). The amount of prescriptions for TCAs increased steadily from 1991 in which it was 4.7 
million to 6.4 million in 2001. It then showed a slight decrease in 2002 to 6.0 million but then 
proceeded to drastically decline to 3.7 million in 2005. The use of other antidepressants had 
shown the greatest amount of growth from being less than 1 million prescriptions in 1991 to 9.9 
million prescriptions in 2005. 
2.2.1 Decline in the use of TCAs 
 
There was found to be an increase in the overall use of antidepressants in a middle-aged and 
elderly  population from 3.9% in 1991 to 8.3% in 2011 (Aarts et al, 2014), this study had showed 
the fluctuation in the prescribing of TCAs. 
Amitriptyline and Paroxetine were the most commonly prescribed antidepressants with 
mirtazapine and venlafaxine being the other antidepressants that were also commonly 
prescribed, but to a lesser extent (Aarts et al, 2014). The study confirms the increased use of 
SSRIs in the elderly and middle-aged population, this is most likely due to the low toxicity, mild 
adverse drug reaction profile and no need for plasma monitoring (Parabiaghi et al, 2011). The 
relatively stable prevalence and slight decrease in the use of TCAs was shown to be consistent 
with the other literature (Parabiaghi et al, 2011) eventhough the researchers expected to see a 
greater decline in the use of these drugs due to their poor tolerability and not being the first 
choice of antidepressant drug in the elderly population (Aarts et al, 2014). The high incidence  in 
the use of TCAs might be explained by the numerous indications for which these drugs are also 
prescribed; this includes neuropathic pain (Raymond et al, 2007). The increase in 
6 
 
antidepressant use in the elderly age groups could also be related to increasing loneliness, 
physical health problems and other disabilities as well as the worsening of chronic diseases 
(Aarts et al, 2014; Parabiaghi et al, 2011). 
 In contrast, a study in Spain showed that the antidepressant that was most frequently 
prescribed was SSRIs at 63.8% followed by TCAs at 18.2% (Serna et al, 2010). This had been 
confirmed in a US based study which showed that SSRI/SNRI type antidepressants were 
prescribed to 71% of the patients in contrast to the 3% of patients that were prescribed older 
antidepressants such as TCAs (Lin et al, 2011). The amount of prescriptions for TCAs 
increased steadily from 1991 in which it was 4.7 million to 6.4 million in 2001, it then showed a 
slight decrease in 2002 to 6.0 million but then proceeded to drastically decline to 3.7 million in 
2005 (Chen et al, 2008).This finding has been mirrored in other studies, one that had been 
conducted over various countries in Europe. TCAs were prescribed for only 1.5% of patients in 
the Netherlands and 8.6% in Austria but accounted for 26.5% of antidepressants prescribed in 
Germany (Bauer et al, 2008). The way in which the prescribing of SSRIs had come to dominate 
was shown in the study by the increase in the number of prescription from 1.0 million in 1991 to 
20.8 million in 2005 (Chen et al, 2008). Of all the 16,886 antidepressants prescribed, 7,044 
(41.72%) were SSRIs, 5,739 (33.99%) were TCAs (Bauer et al, 2008).  
 
  In South Africa, older studies have shown a similar pattern with the most frequently prescribed 
antidepressant, as shown in a study conducted on medical aid data, was TCAs which 
accounted for 40.9% of all antidepressant prescriptions, followed by SSRIs at 34.5% (Truter and 
Kotze, 1997). The prescribing patterns of TCAs were studied using patients who are on a 
private medical aid scheme, data from 1996 (1982 patients) and 2002/2003 (2345 patients) 
were used (Truter and Kotze, 2007). Almost two-thirds of these patients were female (67.41% in 
1996 and 57.53% in 2002/2003) (Truter and Kotze, 2007). Interestingly, TCAs were more 
frequently prescribed to males than females in the younger age groups in 1996 but in the older 
age groups in 2002/2003 (Truter and Kotze, 2006). 
 
 Although the potency of SSRIs are often debated upon, with  their efficacy  being  compared to 
TCAs and other older antidepressants, most psychiatrists and other health professionals agree 
that they should be used as the first choice of drugs because of their less serious  side effect 
profile. An older drug utilization review conducted in Denmark showed  that approximately 75% 
of had TCAs prescribed to patients, whilst SSRIs were only used by 10% of the population 
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(Rosholm et al, 1993). This shows the way in which the use of antidepressants has changed 
over the years. 
 
2.2.2 Prescribing patterns 
 
Antidepressants are often used to treat a number of anxiety related conditions (Gondalez et al, 
2010). They can be used alone or in combination with anxiolytics.  In South Africa, one study 
showed that anxiolytics contributed to the second largest amount of nervous system drugs 
prescribed (Truter and Kotze, 1997). 
In South Africa, of all the SSRIs prescribed, Fluoxetine had been the most frequently prescribed 
with it accounting for 63.3% of all prescriptions, the second most commonly prescribed of which 
was Paroxetine with 28.5% (Truter and Kotze, 1997). In another South African study, female 
patients (62.33%) were more frequently prescribed SSRIs and SNRIs than males (Van 
Schalwyk and Truter, 2010). In terms of factors influencing the type of antidepressant 
prescribed, there were some socio-demographic factors that had been shown to be associated 
with the type of antidepressant prescribed at the baseline visit. For example, non-smokers, 
younger patients and patients with a higher level of education were more likely to have a SSRI 
prescribed as opposed to any other antidepressant. Interestingly, the researchers had found 
that the type of antidepressant prescribed was not influenced by factors such as severity of 
anxiety, current patient functioning or co-morbidity. 
In South Africa, the health sector is divided into the private and public sector. The private sector 
provides health care to patients who have a medical aid fund which allows access to private 
(non-government owned) hospitals and other health care services. Within this sector, 
prescribing is not limited to a list of drugs however it is controlled by the availability of that drug 
in South Africa as a whole. Within the public health sector, which is state controlled, prescribing 
is controlled by a list of approved drugs known as the Essential Drug List (EDL). The purpose of 
such a list is to ensure adequate and safe supply of effective and safe medicines in the most 
cost-effective manner to all citizens of South Africa.  
The criteria for the selection of essential drugs for Primary Health Care in South Africa were 
based on the WHO guidelines for drawing up a national EDL. They include the following: 
• any drug included must meet the needs of the majority of the population 
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• sufficient proven scientific data regarding effectiveness must be available 
• any drug included in the EDL should have a substantial safety and risk/benefit 
ratio 
• all products must be of an acceptable quality, and must be tested on a continuous 
basis 
• the aim, as a rule, is to include only products containing single pharmacologically 
active ingredients 
• combination products, as an exception, will be included where patient compliance 
becomes an important factor, or two pharmacologically active ingredients are 
synergistically active in a product 
• products will be listed according to their generic names only• a request for a new product to be 
included on the EDL must be supported by 
scientific data and appropriate references on its advantages and benefits over an 
existing product. 
The standard treatment guidelines characterize depression as a depressed mood (sadness) 
accompanied by loss of interest and decreased experiencing of pleasure as well as social 
withdrawal. With regards to prescribing, the choice of antidepressant is guided by the comorbid 
conditions eg cardiovascular disease and in the elderly. TCAs are avoided in cardiovascular 
disease and SSRIs are used with caution in the elderly. According to the EDL, the first line for 
treatment of MDD are the TCAs amitriptyline and impramine. The second line treatment is the 
SSRIs citalopram and fluoxetine (Department of Health, 2012). In the private sector, there is a 
larger variety of antidepressants available which does not limit prescribing to just two classes, 
as with the public sector. 
 
 
 
2.2.3 Antidepressant use in patients under 20 years of age 
 
A study to show the prescribing patterns in patients younger than 18 showed that SSRIs 
accounted for 55.91% of antidepressant prescriptions which was ahead only of TCAs which 
contributed to 32.32% of prescriptions. These two antidepressants accounted for 79.49% of the 
antidepressant cost (Truter, 2010). Another study which had aimed at investigating the 
prescribing patterns of SSRIs and SNRIs in patients 19 and younger showed that 440 patients 
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younger than 19 years receiving antidepressant therapy which had accounted for 6.20% of 
patients of any age receiving antidepressants (Van Schalwyk and Truter, 2010). The average 
age of these patients was 14.21 (SD=3.05) years with the majority of patients being older than 
12 years old (77.13%) (Van Schalwyk and Truter, 2010). Antidepressants prescribed to patients 
18 and younger, from a private medical scheme database, 12549 antidepressant prescriptions 
were made  to this patient population out of the total of 814540 antidepressant prescriptions  in 
the year 2009 (Truter, 2010). Another study which had been done in the US had shown that 
younger patients were more likely than older patients to receive an SSRI (Bartels et al, 1997). 
A study in Germany aimed at describing the antidepressant drug use and off-label prescribing of 
antidepressants in the child and adolescent population. The SSRI fluoxetine and only a few 
TCAs as well as the herbal treatment for depression, St John’s Wort, had been licensed for the 
treatment of depression in children and adolescents in Germany (Dorks et al, 2013). The study 
revealed that the prevalence of antidepressant use was 1.84 per 1000 children in 2004, 1.57 in 
2005 and 1.66 in 2006 (Dorks et al, 2013). From the children treated with antidepressants, 
56.30% had been diagnosed with a depressive disorder. From these patients, 43.14% received 
one prescription, 18.36% received two, 10.88% received three and 27.62% received more than 
three antidepressant prescriptions. Of all the 16,886 antidepressants prescribed, 7,044 
(41.72%) were SSRIs, 5,739 (33.99%) were TCAs, 2656 (15.73%) were St John’s Wort and 
1,447 (8.57%) were other types of antidepressants. Of all the antidepressants prescribed, 
13,035 (49.11%) were for off-label antidepressant use, meaning it had been prescribed for 
conditions other than its registered indications. The researchers also found that the off-label use 
by age (40.18%) was more common than the off label use by indication (16.63%) which showed 
that younger patients would be more likely to be prescribed an antidepressant for indications 
other than depression. This appears to be a trend even though the use of antidepressants is not 
recommended in children and adolescents because of an increase in the risk of suicide as 
shown with the black box warning.  Regulatory bodies have warned about the use of 
antidepressants particularly in the first few weeks, the use of antidepressants remain prevalent 
regardless of risk of suicide associated with these drugs (Courtet et al, 2014). 
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The results of the study showed clearly that the prevalence of antidepressant use did not vary 
much over the study period from 2004 to 2006. From all the patients treated with 
antidepressants, most of the patients received single prescriptions and TCAs accounted for a 
majority of all antidepressants prescribed. The proportion of SSRIs, mainly fluoxetine, use 
increased during the study period while the proportion of use of St John’s wort decreased 
(Dorks et al, 2013).  
 
2.3 Gender in antidepressant studies  
 
Through a number of studies, the prevalence of depression had been shown to be higher in 
women than in men. Studies done in both Europe and South Africa have showed the same 
findings. A Danish study showed that among a group of patients diagnosed with depression 
over a long period of time, 59.69% were female (Grasse et al, 2013). This finding is confirmed 
by other studies which show that depression is treated and diagnosed half as frequently in male 
than in female patients (Truter and Kotze, 2006).  
Often the question is raised as to whether depression is more prevalent in women or whether 
women seek treatment more frequently than men.  
Another European based study which had showed statistics, from a sample of people whom 
come from various countries, which further encouraged the theory that depression is more 
prevalent in women (Bauer et al, 2008; Aarts et al, 2014; Serna et al, 2010). In the United 
States, similar findings were reported with 70% of the population who were receiving 
antidepressant therapy being women (Lin et al, 2011). A study in Spain showed that 67.1% 
were female and the average age of the patients was 51 (Serna et al, 2010). A study in the US 
showed that of the 2 111 615 patients, all of whom were adults that have been diagnosed with 
MDD, 70% were female (Lin et al, 2011). The same findings were shown here in South Africa. A 
South African study conducted on 2117 patients showed that 72.8% of the patients were female 
with the remainder 27.2% being male (Truter and Kotze, 1997). In 2009, results from a private 
medical aid scheme in South Africa showed that of these patients, on antidepressants, 53.74% 
were female (Truter, 2010).  The results from the South African mental health and stress study 
shows that there were more females than males who had received treatment or sought medical 
attentions because the group consisted mostly of females (53.7%) (Tomlinson et al, 2009). 
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Another South African study on mental health patterns had shown that women were more likely 
to seek treatment overall however, among 12-month cases there had been no significant gender 
differences for mood disorders, this difference could be because women more of a tendency to 
recognize symptoms of affective distress than men over a long term period (Seedat et al, 2009). 
There have been deviations in the proportion of male to female when younger age groups of 
children and adolescents had been studied for the off-label use of antidepressants, where the 
proportions are almost equal (Dorks et al, 2013). Depression is more prevalent in women than 
in men, therefore when antidepressants are prescribed for off-label conditions, the gender 
differences is minimal. This is mainly due to the fact that the off-label conditions, for which 
antidepressants are prescribed, are found in near equal proportions in both males and females.  
The manners in which antidepressants are prescribed differ between the two gender groups as 
well. Female patients (62.33%) were more frequently prescribed SSRIs and SNRIs than males 
(Van Schalwyk and Truter, 2010). In 1995, of a total of 2117 patients on fluoxetine, 72.8% were 
female and 27.2% were male (Truter and Kotze, 1997). TCAs were more frequently prescribed 
to males than females in the younger age groups in 1996 but in the older age groups in 
2002/2003 (Truter and Kotze, 2006). This could be largely due to the fact that TCAs are now 
being used more for their off-label uses such as neuropathic pain.  
 
 
2.4 Patient Ethnicity in relation to antidepressant prescribing 
 
Differences in depressive symptoms as well as the prevalence of depression are found to vary 
among various ethnic groups. There have been a number of studies to show which ethnic 
groups are affected most by depression. An American based study, which aimed to show the 
prevalence of depression among the minority groups, showed that the prevalence is higher in 
Puerto Rican patients, with the lowest being among Chinese and Filipino groups (Gondalez et al 
2010). Another similar study showed that there is also a difference in the types of symptoms 
reported among ethnic groups with Latino patients reporting more symptoms than White or 
African-American groups (Kemp et al, 1999). The finding that patients of a Hispanic origin 
exhibit more depressive symptoms than any other ethnic group in America had been confirmed 
in a previous study which showed that Mexican Americans showed higher levels of depression 
than White and African-American patients (Neff and Hope, 1993). On the opposing end of the 
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spectrum, a more recent study showed that African-Americans and Hispanics showed lower 
rates of depression when compared to Caucasian patients (Williams and Sternthal, 2010) 
Studies have shown the varied beliefs of depression and its treatment between different ethnic 
groups with ethnic minority groups being less likely to believe that the cause of depression is a 
biological change (Givens et al, 2007). These same minority groups had also less faith in using 
antidepressants in the treatment of depression, they had been more likely to believe in non 
pharmacological treatment such as counseling and prayer as these patients felt that 
antidepressants were addictive (Givens et al, 2007). 
In South Africa, there had not been many studies done to show which of the ethnic groups have 
been most affected by depression. Results from the South African stress and health study 
analysed 4351 adult South Africans of all ages and all racial groups. The sample of patients had 
been diagnosed with either a 12 month or lifetime major depression (Tomlinson et al, 2009). 
The group consisted mostly black patients (76.2%) followed by coloureds (10.4%), white (3.4%) 
and Indian/Asian (3.4%) (Tomlinson et al, 2009). The prevalence of depression in this study 
group was proportionally consistent with the demographic of our country which consists of 
76.4% Black, 9.1% White, 8.9% Coloureds and 2.5% Indian or Asian, with the exception of 
white and coloured patients (STATS SA, 2012). 
With regard to the type of antidepressant chosen for each group, one study that had been 
conducted using Medicaid patient information in the US had shown that the patient’s race had 
an influence on the type of antidepressant prescribed (Melfi et al, 2000). The study had shown 
that of all those patients receiving antidepressant therapy, whites were found to be more likely 
than patients of an African descent to have been given SSRIs. 
2.5 Age groups that were frequently prescribed antidepressants 
 
Age is one of the most important patient factors to consider when conducting any drug utilization 
review (Worster, 2004). With regards to an antidepressant drug utilization review, it not only 
provides information on the type of antidepressants prescribed to each group but also on the 
age groups which are more likely to be affected by depression. The results of a stress related 
study in South Africa showed that the average age of patients diagnosed with depression was 
37.0 years (Tomlinson, et al, 2009) whilst another South African study showed a much different 
result with the average age of patients in that study on antidepressants was 53.4 (SD= 14.5 
years), the average age of the male participants was 54.0 (SD=15.4 years) and the average of 
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the female patients were 53.2 (SD=14.2 years) (Truter and Kotze, 1997). A study in Spain 
showed that the average age of the patients was 51 (Serna et al, 2010).  In certain European 
countries the average age of patients receiving antidepressant therapy had been slightly lower 
than shown here at 46.8 (SD=14.7) (Bauer et al, 2008). In the Netherlands, researchers had 
used a patient population consisted of 14,926 patients who were receiving antidepressant 
therapy, which had shown that this group presented with the average age of 65.5 years 
(SD=10.5) (Aarts et al, 2014). In contrast, one US based study showed that elderly patients 
were less likely to spend on MDD drugs as compared to patients aged between 18 and 25 years 
(Lin et al, 2011).  
 
Over the progression of the past two decades, the use of antidepressants in adolescents, 
children and young adults has increased tremendously (Zito et al, 2006). This study showed that 
TCA were the most frequently prescribed antidepressant in 1988 but this had shifted to SSRIs 
by the year 1994. A commission on safety of these drugs in 2003 reviewed results from 
antidepressant drug trials in the United Kingdom which showed that venlafaxine, should not be 
used because of its lack of efficacy in treating depressive disorders and the increased risk of 
harmful results such as suicidal ideation and hostility in children aged 6-17 (Vitiello and Swedo, 
2004). A year after that result, the UK had extended  that warning to include SSRIs as well, 
soon after the United States Food and Drug Administration (FDA) issued a black box warning 
for all SSRIs and SNRIs due to the increased risk of suicidal ideation in studies with children 
who have been diagnosed with major depression (Kennedy, 2006).  
2.6 Depression has an effect on work productivity 
 
A decreased amount of productivity as well as absenteeism at work are both factors that have 
been associated with depression (Gasse et al, 2013). Financial burdens, increased work stress 
as well as the ever present threat of recession are all factors that can contribute to the 
deterioration of an individuals mental state.  A high rate of unemployment is often shown in 
patient groups who are undergoing treatment for depression. There is speculation as to what 
causes this trend with some researchers investigating the effects of depressed patients taking 
sick leave for longer than 8 weeks , this high rate of sick leave can be associated to the job 
losses because of depression (Bratberg et al, 2009; Lund et al, 2008). In South Africa, a study 
of a sample population of depressed patients showed that 69.2% of the patients had been 
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unemployed at the time of the study (Tomlinson et al, 2009). There has been much debate as to 
the relationship between work productivity, employment status and depression. One study has 
shown that there is a clear association between mental health and unemployment where there 
is an improvement in a patients mental health when they make a move from unemployment to 
employment whilst those who lose their jobs have been shown to be more likely to develop 
symptoms associated with depression (Murphy and Athanasou, 1999). This shows that 
depression leads to a decrease in productivity which increases the cost to a company. A review 
of the cost associated with a diagnosis of depression showed that depression was associated 
with a large increase in direct and indirect cost, this referred not only to the cost of the drug itself 
but also to costs associated with sick leave and hospitalization (Luppa et al, 2007). Patients with 
depression and anxiety had sought medical treatment from health care facilities more than the 
general population (Wittchen, 2002), as a result this contributed to an increase in the health 
care related cost. Another US based study showed that depressive disorders contributed to $ 
2.1 billion for direct costs (health and social services), $10 billion for loss of productivity and 
$4.2 billion as a result of increased mortality (Stewart, 1998).  
 
2.7 Marital status and depression 
 
The link between marital status and mental health has often been a topic of interest among 
researchers. Some have shown that those who are married or living with a partner have been 
shown to enjoy longer lives because of an improved physical and mental health compared to 
those individuals who were non-married or single (Earle et al, 1998; Ross 1995). Conversely, 
the effects of being married can have a negative effect on an individual’s mental well-being with 
some studies showing that there is a clear relationship between marital dissatisfaction and 
depression (Whisman et al, 2004; Coyne et al, 2002). The rates of divorce are found to be 
greater in patients with a history of a mental disorder, and divorced patients were more likely to 
develop a psychiatric condition (Merikangas et al, 1985; Krohnmuller et al., 2011. The 
adherence to treatment can also be affected by marital status with married men shown to be 
less likely to adhere to antidepressant treatment because of the common side effect of sexual 
dysfunction (Segrave and Balon, 2014).There is evidence of an association between marital 
status, divorce rate and depression. Studies have reported that rates of depression are higher 
among married women than non-married women (Gove, 1972). Some studies have found that 
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there is an association between marital status and the types of antidepressant prescribed with 
people who are married being more likely to be prescribed an SSRI (Bauer et al, 2008; Serna et 
al, 2010). 
 
2.8 Antidepressant costing 
 
The cost involved in treating depression has often been a topic of interest among researchers 
as well (Pan et al, 2014; Sado et al, 2009; Greenberg et al, 2003) . There has been 
considerable debate, since the introduction of SSRIs as first-line treatment for depression, 
regarding the cost-effectiveness of SSRIs and TCAs (Kennedy, 2006). Even though SSRIs are 
considered as a major innovation in psychopharmacology with improved safety, there are still 
on-going investigations comparing the current treatment to the older and cheaper TCAs. These 
investigations have an impact on clinical practice as well as the way in which antidepressants 
are prescribed. 
 
 A study conducted in 2009 aimed at comparing the cost effectiveness of a combination of 
cognitive behavioural therapy and antidepressant therapy versus antidepressant therapy alone 
(Sado et al, 2009). The cost effectiveness had been assessed by determining the incremental 
cost-effectiveness ratio (ICER) per successfully treated patient and then the ICER per quality-
adjusted life years (QALYs). The study had found that the combined therapy had led to an 
increase in the rate of successfully treated patients, QALY of severe depression and QALY of 
moderate depression by 0.15, 0.08 and 0.04 respectively. The ICER per successfully treated 
patient was JPY (Japanese Yen) 140 418, the ICER per QALY of severe depression was JPY 
268 550 and the ICER per QALY of moderate depression was JPY 537 100 (Sado et al, 2009). 
 
 A study conducted in the Netherlands aimed at determining the cost-effectiveness of 
escitalopram in major depressive disorder.  This study found that escitalopram is associated 
with a cost saving of €263 per patient when compared with venlafaxine (Nuijten et al, 2012). A 
recent study in Taiwan aimed at determining which of the antidepressant drug groups were 
more cost effective at treating depression as well as the impact of comorbid cardiovascular 
disease on the economic evaluations of antidepressants. The study had found that compared to 
TCAs and SNRIs, SSRIs were the most cost-effective option as shown by the incremental cost-
effectiveness ratios (Pan et al, 2014). Although TCAs are relatively cheaper, one study has 
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shown that the total health care costs for patients on antidepressants were lower or the same 
for patients on SSRIs as compared to the cheaper antidepressants (Frank et al, 2001).  
 
Thus far, there have been no studies conducted in the public health sector of South Africa that 
reveal the cost of treating a patient with antidepressants, neither as recent study which compare 
the cost effectiveness of antidepressant therapy. A US based study showed that the amount of 
money spent on SSRIs increased as well from $ 64,444,222 in 1991 to 1,502,742,579 in 2005. 
This could be due to an increase in the population however an exponential increase such as 
that could mostly be attributed to an increase in antidepressant prescribing as well as the shift 
from older TCA prescribing to increased use in SSRIs. The expenditure on TCAs increased 
from $ 77,747,994 in 1991 to $ 188,851,359 in 2001 but then decreased to $ 46,237,742 in 
2005. In accordance with the drastic increase in the use of other antidepressants as shown with 
the number of prescriptions, the expenditure increased from $ 17,184,228 in 1991 to $ 
688,814,186 in 2005 (Chen et al, 2008). 
 
The cost of depression spans to much more than just the direct cost associated with medication 
but also include the cost of hospitalization, counseling and loss of productivity at work. The 
direct and indirect costs in the US have risen from $77.4 billion in 1990 to $83.1 billion in 2000 
(Greenberg et al, 2003). Thought the initial costs do seem substantial, the increase within that 
time period can also be attributed to the growth of the population which therefore reflects as an 
increase in the number of people using the antidepressants. In Europe costs related to mood 
disorders (including depression) have been estimated at €114.4 billion, half of which is 
attributed to the indirect cost, with sick leave contributing for a large amount of these 
(Gustavsson et al, 2011).   
Chapter Summary 
The burden of depression is prevalent not only in the US and Europe but also in South Africa. 
The prescribing of antidepressant has changed over time, with some antidepressants now being 
favored more than others. Drug utilization reviews have been done worldwide to measure the 
extent to which these antidepressants are prescribed as well as the patient demographics to 
which these drugs are frequently prescribed to. Health care in South Africa is divided into two 
sectors, namely the private and public sector. To measure the way in which antidepressants are 
prescribed, a retrospective drug utilization review had been done using data from the public 
sector.   
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Chapter Three: More about depression and its treatment (Background 
Information) 
3.1 Depression 
 
Depression is a psychiatric disorder that has become increasingly common in South Africa (Van 
Schalwyk and Truter, 2010). In terms of years lost to disability, depression is described as the 
most disabling medical condition, and it has been projected that by 2030, depression will 
become the highest contributor to the worldwide burden of disease (WHO, 2008). The 
characteristics of depression in a patient are a profoundly negative view of the future, 
themselves and the world as well as a decreased response to previously pleasurable events; it 
is this negative view of the world that has been related to negative effects in interpretation, 
memory and attention (Mathews and MacLeod, 2005). The typical symptoms of depression 
include anhedonia, constant depressed mood, slowed reaction time, poor concentration and 
memory, appetite disturbance which can result in weight change, loss of libido, sexual 
dysfunction, non-localized pain, low energy, inappropriate guilt, worthlessness, suicidal ideation, 
, altered sleep patterns and daytime fatigue (Naismith et al, 2012). The average suicide 
attempts among depressed patients is shown to be 180 – 400 per 100 000 as opposed to the 10 
– 25 per 100 000 average among non-depressed patients (Unverir et al, 2006). Depression is 
regarded as a very serious condition, it is not to be underestimated with an estimated lifetime 
prevalence of 20% and large amount of patients (30%) who do not show any kind of response 
to treatment (Pederson et al, 2008). 
 
3.1.1 Prevalence of depression 
 
The burden of mental disorders is one that is ever increasing in all regions of the world, 
neuropsychiatric disorders now contribute around 14% of the global burden of disease (Prince 
et al, 2007). Within the coming decades, depression has been projected to become the second 
leading cause of disability worldwide and the leading cause of disability in first world countries 
such as the US (Mathers and Loncar, 2006). In New Zealand, the prevalence of depression 
increased 35% over a period of 5 years (Read et al, 2015). In the UK prescriptions for 
antidepressants increased by 10% each year between 1998 and 2010 (Illyas and Moncrieff, 
2012). The World Health Organisation study of the Global Burden of Disease estimates that by 
the year 2020, the resultant disability from depressive illness will be second only to 
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cardiovascular disease (Murray and Lopez, 1997). In a European study which surveyed data for 
the European union plus Iceland, Norway and Switzerland showed that depression has been 
estimated to affect 6.99% of the population 14 years and older therefore affecring 30.3 million 
people per year, making depression rank number 1 for Disability Adjusted Life years lost 
(Wittchen et al, 2011). Depression is also found to be present in children with a prevalence of 
0.4% to 2.5% in primary school children, and from 0.4% to 8.3% in adolescents (Birmaher et al, 
1996). In line with the international patterns of depression, the lifetime prevalence of major 
depression in South Africa is estimated at 9.7% (Tomlinson et al, 2009). With regard to the 
disease burden in South Africa, neuropsychiatric conditions rank third in their contribution to the 
burden of disease, after human immunodeficiency virus/ acquired immune deficiency syndrome 
(HIV/AIDS) and other infectious diseases (Lund et al, 2010). 
An epidemiological study conducted between 2002 and 2004 revealed that the prevalence of a 
major depressive episode in South Africans was 9.8% for a lifetime and 4.9% for within the past 
12 months (Tomlinson et al, 2009). It has also been shown that 16.5% of South Africans suffer 
from either severe anxiety or depression and 43% of people with HIV across provinces 
presented with a mental disorder (Williams et al, 2007). Studies that have been conducted in 
rural areas have found a prevalence rate of the symptoms of depression to be 18% and a rate 
of depression of 27% whilst urban areas are found to have a prevalence of depression of 25.2% 
(Tomlinson et al, 2009). 
Depression has been shown to be twice as likely to occur in women as in men (Rihmer and 
Angst, 2008). As shown in a number of other studies, there are more female patients receiving 
antidepressant therapy than males. Other antidepressant drug utilization reviews that have used 
patient information from countries in Europe have reported the same findings where there had 
been more than 65% of the entire patient population consisting of females (Bauer et al, 2008) 
(Aarts et al, 2014) (Serna et al, 2010). The same has been shown in the United States, only 
more so, with a 70% of the patient population on antidepressant therapy being females (Lin et 
al, 2011). The higher prevalence of depression in females than males can be directly linked to 
this as it is known that depression has been shown to be twice as likely to occur in women as in 
men (Rihmer and Angst, 2008). This is largely so when the patient population has a variation of 
age ranges. There have been deviations in the proportion of male to female when younger age 
groups of children and adolescents had been studied for the off-label use of antidepressants, 
where the proportions are almost equal (Dorks et al, 2013).  
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3.1.2 Psychobiology of depression 
 
Stress has often been associated with the onset of depression. The vulnerability of individuals to 
psychiatric disorders such as depression varies greatly. The diathesis/stress model helps to 
understand this variability by considering issues such as vulnerability (the diathesis) and 
precipitation (the stress) (Monroe and Simons, 1991). This model shows that as an increase in 
the diathesis occurs, there is a lower level of stress needed to precipitate an episode of 
depression and the occurrence of an episode of depression itself increases the diathesis for 
episodes that may occur in the future (Willner et al, 2012).  
The diathesis can occur in numerous different ways and at a variety of stages within the life 
cycle that can render an individual more likely to have a depressive episode. Many adverse 
early life experiences have been shown to cause an increase in the risk of depression (Slavich 
et al, 2011). Psychological, psychosocial and biological processes contribute to the mechanism 
by which these early life experiences increase the risk of developing depression through 
conversion of these traumatic experiences into long-term vulnerabilities (Slavich et al, 2011). 
This is shown as absent or poor care by parents or loss of a parent which leads to lowered self-
esteem and emotional instability, this in turn leads to a lowered ability to form close 
relationships, thereby minimizing the quality of social support available, a factor that is 
considered a vulnerability to depression (Schoenfelder et al, 2011).  
Methods of processing information are also determined by these early life experiences for 
example, the negative thinking pattern that is always found in depressed patients often reflects 
a negative cognitive system that is acquired through adverse experiences in childhood such as 
criticism, having a depressed parent and rejection (Willner et al, 2012).  There is also an 
increased potential for beginning a depressive episode among individuals who have 
experienced a major adverse life event such as bereavement or it can also be attributed to a 
combination minor events such as poverty, family conflict, unemployment, chronic illness or 
even unwanted pregnancies (Farmer and McGuffin, 2003). 
 
 Another factor which reflects early life experiences but is also inheritable is personality factors 
that combines with both social and cognitive factors to contribute to the development of 
depression (Compass et al, 2004). Neuroticism, a personality factor, is the strongest risk factor 
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for depression and greatly influences the effect of genetics and early life experiences on chronic 
depressive symptoms (Kendler and Gardner, 2011). 
 
3.1.3 Effect of stress 
 
The hypothalamic pituitary adrenal (HPA) axis is a major physiological system that is activated 
as a result of stress. This physiological system involves the release of corticotropin releasing 
hormone (CRH) from the paraventricular nucleus within the hypothalamus which causes the 
production of adrenocorticotrophic hormone (ACTH) from the pituitary gland, this stimulates the 
release of the glucocorticoid, cortisol, from the adrenal cortex into circulation (Holsboer and 
Ising, 2010). The release of cortisol has a negative feedback effect on the hypothalamus that 
helps to control the activation of the HPA axis. The amygdala as well as descending pathways 
from the forebrain relays emotional stimuli to the HPA axis, as a result this has a stimulatory 
effect (Willner et al, 2012).  An inhibitory control of the HPA axis is exerted by the hippocampus 
through a negative feedback loop whereby cortisol is used to inhibit the HPA axis (Holsboer and 
Ising, 2010). 
 
 
 
 
 
 
 
 
 
 
21 
 
 
 
 
 
 
 
 
 
 
 
Fig 3.1: The effect of stress on the HPA axis is shown as it stimulates the release of CRH from 
the hypothalamus. As a result, ACTH is released from the anterior pituitary which causes the 
adrenal gland to secrete cortisol, the release of which has its own metabolic effects and has a 
negative feedback effect to inhibit the release of CRH (Holsboer and Ising, 2010). 
 As a result of persistent stress, chronic exposure to cortisol can be neurotoxic, this is because it 
leads to a loss of sensitivity of the glucocorticoid receptor (GR) which further causes increases 
in cortisol through the lack of an inhibitory effect on the HPA axis  (Willner et al, 2012). If the 
loss of GR sensitivity persists, the hyper-stimulatory effects on the HPA axis can have severe 
effects such as production of neurotoxic free radicals as a result of hyperactivity of calcium-
dependant enzymes, decreased production of brain derived neurotrophic factor (BDNF) and a 
lowered transport of glucose into the cell which results in a loss of energy capacity (Willner et al, 
2012). The evidence of a decrease in BDNF levels during chronic exposure to stress is shown 
by a study which found decreased BDNF in the hippocampus of patients who had committed 
suicide (Karege et al, 2005). 
One of the main effects that chronic exposure to cortisol had been found to cause is an increase 
in the activity of MOA-A, an enzyme which causes the breakdown of the monoamines NA and 
5HT, thereby causing a decrease in these neurotransmitters (Willner et al, 2012). This is further 
proven by neuroimaging studies which found an increased MAO-A activity in the brains of 
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depressed patients (Meyer, 2012). These findings help to further augment the theory of 
decreased levels of 5HT and NA in depressed patients. Among these changes caused by 
chronic exposure to glucocorticoids are the neurochemical and structural changes that occur in 
the hippocampus and closely resemble that of depressed patients (Willner et al, 2012). Chronic 
exposure to high levels of glucocorticoids can also cause damage to other areas of the brain 
such as the prefrontal cortex in addition to the damage caused to the hippocampus (Willner et 
al, 2012).  
Prolonged exposure to stress and elevated levels of cortisol has also been linked to the 
anhedonia that depressed patients’ experience. Anhedonia is the inability to experience 
pleasure and is a core symptom of depression. This symptom has been associated with a 
lowered activity in the mesolimbic dopamine (DA) projection from projection from the ventral 
tegmental area (VTA) of the midbrain to the nucleus accumbens (Treadway and Zald, 2011).  
CRH has been shown in a recent study to cause a release of DA from the nucleus accumbens 
which results in a rewarding effect however, after exposure to severe stress, CRH can no longer 
cause the release of DA instead now has an aversive effect (Lemos et al, 2012). In a similar 
manner to the other symptoms of depression, anhedonia may also be linked to a decrease in 
the hippocampal activity.  
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Fig 3.2: Stress plays a role in the aetiology of depression through the effects of HPA axis 
hyperactivity which leads to hippocampal damage. This damage further leads to a disruption in 
the manner in which information is processed in the forebrain, these disruptions leads to the 
types of symptoms that are then displayed (Willner et al, 2013). 
 
3.1.4 Adverse events in childhood related to depression 
 
There has been a large amount of research which has shown that adverse events during 
childhood such as sexual, physical and verbal abuse as well as exposure to foster care are 
major factors that can contribute to the aetiology of depression in individuals later in life (Mersky 
et al, 2013; Widom et al, 2007; Dube et al, 2010). Within this theory of depression which 
focuses on early childhood stressors, there are two hypotheses which are used to explain the 
variation of depression within these patients (Riolo et al, 2005). The first is the differential 
exposure hypothesis which states that the variation in mental health outcomes is due to the 
different types of exposure to stressors. This model of stress means that women have more 
symptoms of depression than men because they experience more stressful events and of a 
different kind than that of men (Turner and Avison, 2003). The differential vulnerability 
hypothesis states that at the same amount of exposure there is a variation between individuals 
in the impact of exposure in depression which is largely due to factors of the individual which 
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renders them more or less vulnerable (Turner and Avison, 2003). This basically means that 
women may be more depressed than men because the same type of events has a greater 
effect on women and are more potent stressors for women. 
The effects of physical assault and physical abuse in childhood on the well-being of an adult has 
been well documented with these studies showing that this form of abuse has been associated 
with increased risk of anxiety, substance abuse, depression and mental illness with a greater 
likelihood for the conviction of violent offenses (Roxburgh and MacArthur, 2014). With regard to 
foster care, there is less known about the relation between depression and the lack of a stable 
parenting system. There are theories which suggest that the best way to understand the effect 
that foster care has on an individual in later life is due to factors such as neglect, parental 
substance abuse, unstable living arrangement and multiple transitions between care takers 
which thereby increase the likelihood of poor outcomes in later life such as depression 
(Herrenkohl et al, 2013). This kind of finding has also been supported by another study which 
had shown that for over 60% of eighteen year old individuals who had been transitioning from 
foster homes to adulthood had been exposed to at least one traumatic event, the most common 
of which had been sexual abuse (Courtney et al, 2011). These traumatic events contributes to 
the increasing vulnerability of a patient to depression (Turner and Avison, 2003). 
 
 
3.1.5 Neurobiology of depression 
 
The monoamine neurotransmitters noradrenalin (NA), serotonin (5-HT) and dopamine (DA) 
facilitate transmission in neural pathways that originate in the brainstem have numerous 
ascending projections to the limbic system and cortex as well as descending projections to the 
autonomic nervous system (Nutt, 2002). Aspects of behavioural function which includes mood 
and anxiety are controlled by these pathways. A deficiency of monoamines has been implicated 
by early theories in the physiology of depression This is largely evident because drugs that 
facilitate the release of monoamine (e.g. amphetamine)  had been found to be show 
antidepressant action , while drugs that inhibit the release of monoamine (e.g. reserpine) show 
depressive symptoms in patients after administration (Nash and Nutt, 2007).  
Post-mortem evidence in which neuroendocrine and neuroimaging studies have been 
conducted showed that depression is associated with abnormalities of postsynaptic monoamine 
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receptor function; some antidepressants have direct actions on these receptors (Nutt, 2002). 
Numerous clinical and preclinical studies indicate that a disturbance in serotonergic activity may 
be associated with major depression. Noradrenergic and dopaminergic neurotransmission has 
also been implicated (Artigas, 2015).  
3.1.6 Monoaminergic role in depression 
 
Throughout the years of investigation about the root cause of major depression, it is still 
believed that a lack of function and hypo activity of the monoaminergic system have been 
assumed to be the cause of the symptoms of depression. This assumption had mainly been 
based on the observation that antidepressant drugs increase the activity and thus the function of 
monoaminergic systems, in particular serotonin and norepinephrine (Artigas, 2015). One 
common charactersitic of these ascending monoaminergic systems is that their cell bodies are 
found in the brainstem and that their activity is strictly regulated by the prefrontal cortex (PFC), a 
cortical area where metabolic abnormalities have been reported in depressive patients.  
 
Therefore, the locus coeruleus, the raphe nuclei and the ventral tegmental area, where the cell 
bodies of ascending noradrenergic, serotonergic and dopaminergic neurons are found, 
respectively, receive dense afferents from dorsal and ventral parts of the medial prefrontal 
cortex in rodents, which are equivalent to dorsal and ventral cingulate areas in primate and 
human brain (Groenewegen and Uylings, 2000).  
Electrophysiological studies have shown that the activity of monoaminergic neurons is tightly 
regulated by these descending afferents via direct (e.g., monosynaptic) or indirect (via local 
interneurons) inputs (Jodo et al, 1998). Therefore, metabolic changes in the anterior subgenual 
cingulate can affect the functional relationships between limbic and cortical areas, a change that 
has been shown to lead to the depressive illness (Seminowicz et al, 2004). The metabolic 
changes in ventral cingulate areas can often cause a functional hypoactivity of the ascending 
monoamine systems that can as well add to the depressive symptoms, given the involvement of 
monoamines in mood, anxiety, affect, cognition, sexual drive, sleep. The treatment with 
antidepressant drugs would restore monoamine function in cortical and limbic areas, thus 
improving depressive symptoms. 
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3.1.7 Serotonin relation in depression and treatment 
 
Physiological and anatomical characteristics of 5-HT neurons are relevant for the action of 
antidepressants; the same points of action are often shared with noradrenergic neurons. The 
release of serotonin and serotonergic activity in the forebrain is a very strictly controlled 
process, which is regulated by a number of pre-synaptic and post synaptic mechanisms which 
have been refined through the years of human development to keep a tonic and regular activity 
of the serotonin neurons (Artigas, 2015). This demonstrates that when antidepressants aim at 
increasing the amount of serotonin released, it interferes with the homeostasis of the 
serotonergic system thus activating self-adaptive systems and mechanisms that limit the full 
working potential of the antidepressant (Wong et al, 2008).  
 
Extensive research has been dedicated to the investigation of the way in which different 5-HT 
receptors can have an influence in the treatment and pathophysiology of major depression. 
There has been interest into this particular receptor as researchers are trying to find novel ways 
in which antidepressant treatment can be enhanced by bypassing or breaking the adaptive 
mechanisms to cause a greater and increase in extracellular serotonin. Among all the serotonin 
receptors that have been studied, the one that is shown to be of most interest is the 5-HT1A 
receptor. This is mainly because the 5-HT1A receptor abnormalities have been found in patients 
with major depression thus have been a target for numerous antidepressants. With this in mind, 
it is then clear to understand why many post-mortem and genetic studies have revealed that 
patients with a higher level or activity of the 5-HT1A autoreceptors are much more susceptible 
to mood disorders and also have displayed a poor response to antidepressant treatment 
(Lemonde et al, 2003). To support this finding, it has been proven that a lowered 5-HT1A  
receptor binding potential has been found in patients with major depression that have recovered 
compared to control subjects, this has in turn caused the belief that suggests that low 5-HT1A 
receptor density may give rise to vulnerability to major depression (Bhagwagar et al, 2004).  
 
When an SSRI or SNRI is administered, the excess serotonin activates somatodendritic 5-HT1A  
autoreceptors and hyperpolarizes 5-HT neurons which therefore oppose the incoming excitatory 
inputs (Artigas, 2015). In this way, antidepressants cause an over-activation of this physiological 
feedback mechanism by having a greatly increased extracellular amount of serotonin in the 
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raphe nuclei, which is the region that contains the greatest amount of serotonin transport 
systems in the brain, therefore this causes a decrease in serotonergic activity and release of 
serotonin in the forebrain. With this finding, there are currently numerous researchers that are 
investigating ways in which the autoreceptor can be antagonised so that antidepressant effect 
can be enhanced.  
Another serotonergic receptor that has become of great interest to researcher is the 5-HT2A 
receptor. It has been widely documented that a number of antidepressants and antipsychotic 
drugs bind with a high affinity to this receptor, thus showing the potential that this receptor has 
to play an important role in depression (Artigas, 2015). There have been numerous clinical 
studies which suggest that atypical antipsychotic drugs have increased the clinical response to 
SSRIs in treatment resistant patients (Carvalho et al, 2009). As a new discovery, it has been 
made known that 5-HT3 receptor antagonism or receptor blockage had the ability to potentiate 
the increase of extracellular serotonin produced by the SSRI citalopram in the rat (Mork et al, 
2012). Also, it has been shown that administration of an agonist of serotonin in the rat brain 
modifies key markers that are considered to be important in depression which enhanced 
phosphorylation of CREB protein and neurogenesis in the hippocampus (Lucas et al, 2007).  
3.1.8 Use of antipsychotics in the treatment of depression 
 
There have been a number of studies which have shown that there is a beneficial effect to 
adding on an atypical antipsychotic drug to current treatment with an antidepressant. This is 
particularly evident in treatment with SSRIs that is found in drug resistant depression. Although 
antidepressant therapy is found to initially alleviate and decrease the symptoms of depression in 
many patients, only 50 to 60% of patients with major depression show a positive response to 
antidepressant treatment (Rogoz, 2013). These atypical antipsychotics are olanzapine, 
ariprizole, ziprasidone, quetiapine and risperidone. These are agents that have been found to 
potentiate the effects of antidepressants (Wright et al, 2013). Atypical antipsychotics have the 
potentiating effect on antidepressants by binding to serotonin receptors with a greater affinity 
than dopamine receptors; they also bind to histamine receptors and adrenergic ones as well 
with ariprazole showing an strong tendency to show activity at 5-HT1A receptors (Jordan et al, 
2002). 
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3.1.9 Social opinions on depression 
 
The common belief among the public regarding mental health problems have often being a 
subject of interest. This is largely because of the relationship to stigma about recovery. Mental 
disorders such as psychosis, schizophrenia and depression have often been related to 
increased stigma in the community as well as the decreased expectation of recovery (Read et 
al, 2014). The common view of the public, which has proven to be quite resilient, is that the 
treatment of depression should rather consist of a psycho-social treatment over a bio-genetic or 
pharmacological treatment approach (Hughes et al, 2011). In Germany, it has been a common 
belief that “brain disease” as a cause of depression increased from 25% to 38% between 1993 
to 2001, with a slight increase from 37% to 40% for “hereditary” causes, “partnership problems” 
and “work stress” had been identified far more frequently recognised with increases of 73% to 
81% and 75% to 80% respectively (Angermeyer et al, 2013). A study in Sweden had shown that 
69% of depressed patients recognised current life stressors, mostly from work and family, and 
life events of the past (32%) as the main cause of their depression (Hannsson et al, 2010). A 
similar study in Austria has shown the belief in “inherited or genetic” increased from 49% in 
1995 to 65% in 2011, where they had regarded “day to day problems” and “death of a close 
friend and relative” and “problems in childhood” as one of the greatest causes for depression 
(Pilkington et al, 2013). Studies have shown that depressed patients were much likely to label 
psychosocial stress as the cause of depression compared to the opinion of non-depressed 
patients and that patients who had received treatment for depression had a greater likelihood 
than non-depressed patients to label conditions of socialisation such as adverse childhood 
occurrences and less likely to label biological factors as the cause of depression (Mnich et al, 
2014). Depressed patients were however more likely to blame psychosocial stressors rather 
than biological or genetic factors but to a lesser extent, compared to the general population, as 
the cause of their depression (Pilkington et al, 2013). This means that depressed patients have 
a greater recognition for the role of biological factors than that of the general public.  
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3.2 Diagnosis and Treatment of depression 
 
A diagnosis of depression is made using as set of criteria known as the Diagnostic and 
Statistical Manual of Mental Disorders (APA, 2013). This manual helps to classify the different 
types of depression for a targeted approach to therapy. 
3.2.1 Major depressive disorder 
 
DSM-V Criteria for Major Depressive Disorder (MDD) includes a depressed mood or a loss of 
interest or pleasure in daily activities for more than two weeks, impaired social, occupational, 
educational function. At least 5 out of 9 of the symptoms below should persist almost daily. 
These symptoms include: 
1. Daily depressed mood or irritability for a majority of the day 
2. Decreased pleasure or interest in numerous daily activities 
3. Change in appetite that has led to significant weight change (5%) 
4. Insomnia or hypersomnia 
5. Psychomotor retardation or agitation  
6. Fatigue and loss of energy 
7. Inappropriate guilt or feelings of worthlessness 
8. Decreased cognitive ability showing lower ability to think or concentrate as well as more 
indecisiveness 
9. Suicidality, constant thoughts of death or suicide (APA, 2013) 
 
3.2.2 Dysthymic disorder 
 
Dysthymic disorder is a persistent depressive disorder with the same physical and cognitive 
symptoms of depression that is less severe but longer lasting. The DSM-V manual represents a 
diagnosis for dysthymic disorder in the following way: 
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The diagnosis is made if a patient has experienced a depressed mood for a majority of the day, 
on a mostly daily basis that continues for a minimum of 2 years. This includes experiencing of 2 
or more of the following symptoms that has caused a significant impairment in social or work 
functioning: 
1. Change in appetite.  
2. Insomnia or hypersomnia.  
3. Decreased energy or fatigue.  
4. Lowered self-esteem.  
5. Poor concentration or difficulty making decisions.  
6. Feelings of hopelessness (APA, 2013).  
 
3.2.3 Substance-Induced Mood Disorder  
 
Substance-induced mood disorder is defined as a constant and noticeable disturbance of mood 
caused by the direct physiological effect of exposure to a substance. This type of mood disorder 
is commonly found in patients that are undergoing substance abuse rehabilitation or treatment. 
The mood disorder can include depressed mood, mania or a mixture (APA, 2013). This disorder 
has a shorter course than the other depressive illnesses because it only represents itself on 
withdrawal of a substance or during intoxication of the substance (APA, 2013).  
 
3.2.4 Adjustment Disorder with Depressed Mood 
 
The resultant depressive symptoms in this type of disorder occur due the presence intense 
emotional or psychological stress.  The stressor, that can be a recurring situation or an isolated 
event, could manifest itself as family disturbances, divorce, career failure or bereavement. Acute 
adjustment disorder lasts for a number of months but a chronic adjustment disorder can still be 
present long after the stress has occurred (APA, 2013). The symptoms of this disorder are not 
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as severe as those of Major depressive disorder and have the same long duration that 
Dysthymic disorder has (APA, 2013). 
 
3.2.5 Mood Disorder caused by a current Medical Condition 
 
This disorder is characterized by the presence of depressive symptoms that appear to be the 
direct physiological consequence of a general medical condition. This is a type of depression 
that is brought about by the presence of a medical condition such as Parkinson’s disease or 
hypothyroidism. The symptoms of this type of depressive disorder include the following: 
1. Late onset of depressive symptoms 
2. Known underlying medical condition 
3. Atypical presentation of a specific psychiatric diagnosis 
4. Absence of personal and family history of psychiatric illnesses 
5. Illicit substance use 
6. Medication use 
7. Treatment resistance or unusual response to treatment  
8. Sudden onset of mental symptoms 
9. Abnormal vital signs (APA, 2013) 
Depression can also be present as a primary symptom in other psychiatric conditions such as 
posttraumatic stress disorder (PTSD), schizoaffective disorder as well as anxiety disorders that 
include panic disorder, agoraphobia, social phobias and generalized anxiety disorder.   
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3.3 Treatment 
 
The management of patients is a step-wise process. The following describes the initial 
recommendations for patient management as stated by the American Psychiatric Association 
(2010).  
1. Establish and maintain a therapeutic alliance- the physician collaborates with the patient 
in making decisions and considers the patients factors and preferences when deciding 
upon treatment type.  
2. Completion of the psychiatric assessment – a complete patient history is taken which 
includes a general medical history as well as a psychiatric history that includes mental 
status examination, family history of mental disorders as well as response to major life 
events. 
3. Evaluation of the safety of the patient – a careful suicide risk evaluation is done of each 
patient. The risk of the patients harm to themselves or others is evaluated. Suicidal 
thoughts, attempts, plans are identified as well as any general medical conditions that 
can increase the tendency to act on suicidal ideas. The patients’ level of hydration, self-
care and nutrition is also evaluated.  
4. Establish the appropriate setting for treatment – a setting that will protect the safety of 
the patient as well as improve the condition of the patient without being too restrictive. 
5. Evaluate quality of life and any functional impairment – the activity of the patient with 
regard to work, school and family is evaluated as well as the presence of any 
dysfunction. 
6. Collaborate with other health professionals for the care of the patient  
7. Monitor the psychiatric status of the patient – the response to treatment is evaluated. 
8. Enhance the adherence to treatment. 
9. Educate the patient and their family. 
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3.4 Pharmacotherapy 
 
Antidepressants are recommended as the first choice of treatment for patients with mild to 
moderate major depressive disorder (APA, 2010). The choice of type on antidepressant is 
based the individuals patients safety or tolerability to the anticipated side effects. The 
pharmacological profile (half-life, drug interactions, action on cytochrome P450 enzymes etc) of 
each of the drugs is also evaluated to suit the patient. Factors such as patient preference and 
cost are also considered. Selective serotonin reuptake inhibitors (SSRIs), serotonin 
noradrenaline reuptake inhibitors (SNRIs), bupropion and mirtazapine are usually preferred to 
the older tricyclic antidepressants (TCAs) (APA, 2010). The response to treatment as well as 
the emergence of side effects (e.g gastrointestinal symptoms, sedation, insomnia, activation, 
changes in weight, and cardiovascular, neurological, anticholinergic, or sexual side effects) is 
regularly monitored to ensure the safety of the patient (APA, 2010). It is recommended that 
treatment with antidepressants should be commenced and continues to proceed during the 
acute period which is around the phase of four to eight weeks, this is done in order to achieve 
remission at a much faster rate in the acute depressive episode. Treatment is then continued for 
four to five months, this phase is known as the continuation phase and is aimed at keeping the 
patient in remission. After this continuation phase has been completed, which will equate to at 
least six months after the treatment had been started, the physician will then decide based on 
the patients history whether or not the antidepressant treatment should be continued in order to 
prevent the further occurrences of depressive episodes (Serna et al, 2010).  
 
 
Factors to consider when choosing type of antidepressant treatment: 
1. Preference of the patient 
2. Half-life which is the time taken for half of the drug to be metabolized in the body 
3. Cost of the types of antidepressant considered 
4. Response to previous exposure to antidepressant if there had been a previous 
antidepressant used 
5. Relative efficacy and effectiveness of each antidepressant considered 
6. Safety, tolerability, and potential side effects 
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7. Presence of any co-existing psychiatric conditions and general medical conditions 
8. Potential drug interactions with any concomitant drugs a patient may be using before 
commencing treatment with an antidepressant 
Factors to monitor during antidepressant treatment: 
1. Persistence of symptoms and response to treatment 
2. Degree of danger to self and others as well as the potential for suicide 
3. Signs of mania 
4. Presence of other disorders such as alcoholism and substance abuse 
5. General medical conditions 
6. Quality of life 
7. Presence of any side effects to treatment  
8. Patient adherence 
 
3.5 Electroconvulsive therapy 
 
Electroconvulsive therapy (ECT) is used to treat patients that are non-responsive to 
pharmacologic and psychotherapeutic interventions, also in patients with severe major 
depressive disorder and those with impaired functioning who have not responded to various 
types of medication (APA, 2010). This type of therapy is also used in patients who have shown 
catatonic or psychotic symptoms as well as those who have a compromised state of health or 
are severely suicidal (APA, 2013)  
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3.6 Psychotherapy 
 
This type of treatment is initially recommended for patients with mild to moderate major 
depressive disorder. Patients with a presence of interpersonal difficulties or significant 
psychosocial stressors are more likely to have psychotherapy (APA, 2010). In order to assess 
patients response to treatment and safety, psychotherapy treated patients is monitored regularly 
(APA, 2010). In Denmark, 55% of patients with major depression had been treated with 
antidepressants only or in combination with psychotherapy (15%) whilst some patients (30%) 
were receiving psychotherapy alone (OECD, 2012). Individual patient factors such as symptom 
severity, goals and type of therapy, presence of social supports as well as co-operation with 
treatment are considered when deciding upon the frequency of patient visits (APA, 2010) 
3.7 Antidepressant treatment 
 
The first antidepressants to be discovered were the inhibitor of serotonin and noradrenaline 
reuptake, imipramine and the monoamine oxidase inhibitor iproniazid. The use of these 
antidepressants together with electroconvulsive therapy has contributed to a therapeutic 
process which led to the sharp decline of the number of depressed patients being kept in 
psychiatric facilities (Vetulani and Nalepa, 2000). Since the discovery of these initial drugs, new 
compounds with a similar mechanism of action have been synthesised leading to great progress 
in the attempts of improving antidepressant therapy.  
Irreversible monoamine oxidase inhibitors that blocked the action of both the monoamine 
oxidase A and B isoforms were used initially but were later replaced by selectively irreversible 
drugs such as the monoamine oxidase A inhibitor clorgyline or the monoamine oxidase B 
inhibitor selegeline however these drugs have been replaced by a reversible monoamine 
oxidase inhibitor moclobemide (Kennedy, 2006). 
In addition to these improvements in drug therapy, there has been a considerable amount of 
progress with the monoamine reuptake inhibitors. The tricyclic antidepressants such as 
imipramine and amitriptyline which inhibited the reuptake of noradrenaline and serotonin as well 
as acting as antagonists at the Alpha-1, Histamine-1 and muscarinic receptors and were the 
initial choice of treatment had been largely replaced by more selective drugs with less side 
effects. These drugs are the selective serotonin re-uptake inhibitors (SSRIs) such as fluoxetine 
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as well as the serotonin (5HT) and noradrenaline (NA) reuptake inhibitors (SNRIs) such as 
venlafaxine.   
3.7.1 Early theories on antidepressant action 
 
The monoamine hypothesis of depression states that there is a single mechanism for the 
physiology of depression as well as antidepressant therapy, this mechanism shows that 
depression occurs as a result of decreased functioning in 5HT and/or NA which is normalised by 
antidepressants (Willner et al, 2012).  To further prove this theory, studies in which monoamine 
had been depleted in patients consistently showed vital need for functional monoaminergic 
pathways to combat depression; with all currently available treatments aimed at restoring 
compromised monoamine functioning (Delgado, 2000; Millan et al, 2000; Pacher et al, 2001).  
The monoamines have been implicated in the aetiology of depression based upon the 
antidepressant effects shown by hydrazine derivatives such as iproniazid.   
 
3.7.2 Antidepressant drugs mechanism of action  
 
Irreversible monoamine oxidase inhibitors (MAOIs) exert their effect through blockage of the 
enzymes responsible for degradation of monoamines.  Though these enzymes have proven to 
be effective, they are poorly tolerated because of their side effects instead; reversible 
monoamine oxidase inhibitors are preferred because of their better safety margins and 
tolerability (Millan, 2004). There has been considerable debate as to the actual mechanism of 
action of antidepressants on monoamines however, studies in which neurotransmitter depletion 
had been done showed compelling evidence that indeed the mechanism of action of 
antidepressant is as conceived, enhancement of 5HT and NA neurotransmission (Willner et al, 
2012). Though various classes of antidepressants exert their effects through different ways, 
there are some common characteristics that these drugs share. The first mechanism being that 
all antidepressants make use of monoamine systems through their interaction with either the 
catabolic enzymes, receptors or transporters for monoamine reuptake (Millan, 2004). Also, all 
antidepressants act as multi-target agents by acting on numerous receptors in order to increase 
monoamine concentrations. 
 
37 
 
Tricyclic antidepressants (TCAs) such as imipramine and amitriptyline exert their effects by 
blocking the re-uptake of NA and 5-HT however, due to their indiscriminate target profiles; these 
drugs also antagonise α1-adrenoceptors, muscarinic receptors, and histaminergic receptors, as 
well as cardiac ion channels (Schatzberg, 2002). It is this multi target action that gives the TCA 
group of antidepressants their poor tolerability profile. The safest class of antidepressant drugs 
(ADs) is currently the SSRIs, although this class also has a spectrum of side effects, they have 
proven to be better tolerated than TCAs and MAOIs (Millan, 2004).  
Despite their superior safety, SSRIs are not as effective as TCAs; they still are the preferred 
choice of AD treatment in long term depressive states (Millan, 2004). The selectivity of SSRIs 
had been considered the reason for the lower efficacy, this theory led to the development of 
venlafaxine, a serotonin and noradrenaline re-uptake inhibitor (SNRI) (Schatzberg, 2002). 
SNRIs are considered to be more effective than SSRI with a rapid activity even though they 
share the same side effects of SSRIs (Millan, 2004). 
 With the use of antidepressants, there is a delay of 3-4 weeks to reach therapeutic efficacy 
which has proven to be unavoidable and there is still much debate as to whether or not these 
drugs can provide rapid but sustained relief from depression (Wong and Licinio, 2004).  
Although rapid elevations in extracellular levels of monoamines are induced by antidepressants, 
the lag in efficacy is shown to be due to the initiation of neuro plastic events which can include 
neurogenesis, alteration of neuronal architecture, modifications in receptor density and 
intracellular signalling and changes in synaptic transmission as well as architecture (Manji et al, 
2003).  
Transcription factors such as cAMP-responsive element binding protein, effector immediate 
early genes such as Arc, neurotrophins like brain derived neurotrophic factor (BDNF) and anti-
apoptopic proteins such as bcl-2 are the mediators that have been linked to the ability which 
antidepressants have to increase neuronal proliferation and resilience as well as the ability to 
combat changes caused chronic stress and excessive cortisol secretion (Wong and Licinio, 
2004).   Neuronal plasticity as well as cellular models of G-protein/receptor coupling has proven 
to be important factors that contribute to the characterisation of novel antidepressants (Milllan, 
2004). The current limitations of SSRI/SNRI treatments most likely derive from the poor 
knowledge of the pathophysiology of major depression, in common with other psychiatric 
disorders (Artigas, 2015). 
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All antidepressants take at least two weeks before any sort of improvement can be seen. With 
some cases it may take up to eight weeks. Even though the clinical therapeutic effects take time 
before their benefits can be seen, the side effects can be experience immediately. This often 
leads to a decrease in compliancy among patients starting their treatment for the first time.  
3.7.2.1 Fluoxetine and Citalopram 
 
Fluoxetine is an SSRI that is primarily prescribed for conditions such as depression, obsessive-
compulsive disorders, and Bulimia nervosa. It is also prescribed for anxiety disorders, 
particularly generalized anxiety disorders, anxiety and impulse control disorders (Rossiter et al, 
2010).  Fluoxetine is the first choice of SSRI when prescribed to children or adolescents. It has 
to be used with caution in the elderly, patients with hepatic or renal impairment and diabetic 
patients. Elderly patients have been shown to be more susceptible to experience the CNS side 
effects such as agitation, nervousness and excessive sedation. In paediatric patients, fluoxetine 
is shown to be effective in the treatment of depression from the age of seven years old. They 
should however be used with caution in paediatrics due to the fact that all antidepressants have 
an increased risk of suicide in children. Fluoxetine should also be used with caution in pregnant 
patients because of the risk of premature birth. When used in conjunction with other 
serotonergic agents, its been shown to increase the risk of serotonin syndrome which shows 
itself as pyrexia, restlessness, agitation, rigidity and gastrointestinal symptoms. The most 
common side effects are nausea, weight gain, increased appetite, confusion, chest pains, 
palpitations and hypertension (Rossiter et al, 2010). One of the main differences between 
fluoxetine and citalopram is that fluoxetine has a longer half-life (3 days) than all other SSRIs 
whereas citalopram has a lower potential for interaction with other drugs. Fluoxetine is an 
inhibitor of the enzyme CYP2D6 which makes it prone to a number of drug interactions when 
compared to citalopram. Some of the drugs that need to be monitored when used in conjunction 
with fluoxetine include diazepam, warfarin, lithium and carbamazepine.  
Citalopram has been favored for use over amitriptyline due to its better safety profile. It has little 
anticholinergic effects as well as less cardiotoxicity (Rossiter et al, 2010). It has a considerably 
lesser half life than that of fluoxetine (36 hours). Citalopram is a weak inhibitor of cytochrome 
P450 therefore has less drug interactions.  The S-enantiomer of citalopram is known as 
escitalopram which is also a frequently prescribed antidepressant. 
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3.7.2.2.Venlafaxine 
 
Venlafaxine is a serotonin and noradrenaline re-uptake inhibitor (SNRI) which also acts as a 
weak dopamine re-uptake inhibitor. It is mainly used for the treatment of major depression and 
generalised anxiety disorders. It is contra-indicated for use in paediatrics mostly because the 
risk to benefit ratio in patients under the age of 18 had not been established. The most common 
side effects are that of a CNS origin, these include headache, insomnia, dizziness, 
nervousness, visual disturbance and somnolence. Venlafaxine is also shown to cause 
gastrointestinal effects such as dry mouth, anorexia, constipation, nausea and vomiting. It is 
also shown to cause sexual dysfunction, a side effect which has been shown to decrease 
patient compliance. The cardiovascular side effects are hypertension, palpitations, postural 
hypotension and tachycardia (SAMF, 2010). The sexual dysfunction caused by venlafaxine is 
often associated with a lack in adherence (Segrave and Ballon, 2014).  
 
3.7.3 Genetic factors that predict response to treatment 
 
Genetic factors play a very important role in determining the type of clinical response to 
antidepressant drugs, which is then manifested as the behavioural changes noted by physicians 
as progress. Overall, these genetic factors add a further element of complexity to the already 
complex neurobiological elements involved in the clinical response to SSRI and SNRI.  
Polymorphisms of the promoter region of the Serotonin transport system (SERT) have shown to 
be responsible for susceptibility to major depression as well as response to antidepressant 
therapy (Collier et al, 1996). A better response to treatment with SSRIs has been associated 
with heterozygotes and homozygotes of the long variant compared to homozygotes of the short 
variant (Zanardi et al, 2000).  
Single nucleotide polymorphisms in 5-HT related genes such as the previously mention SERT 
and tryptophan hydroxylase 1 also show a relationship with antidepressant treatment response 
(Peters et al, 2004). Increased functioning and expression of 5-HT1a receptors resulting from 
the G (-1019) polymorphism in the promoter region leads also to increased risk for depression, 
poor antidepressant response and suicide (Lemonde et al, 2003). Likewise, catecholamine-
related genes have also been associated to antidepressant response. Phosphodiesterase 
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genes involved in amine signalling pathways and polymorphisms of the KCNK2 gene are often 
associated with a greater susceptibility to major depression and antidepressant response, these 
also have been associated with treatment resistance (Wong et al, 2006). Numerous amounts of 
SNPs in the BDNF gene have been identified, with one of them that have been associated with 
major depression and antidepressant response. 
Polymorphisms of a glucocorticoid receptor related gene known as FKPB5 have also been 
involved in antidepressant response and recurrence of depressive episodes (Binder et al, 2004). 
Also, polymorphisms associated with inflammatory- related genes have also been found to be 
associated with susceptibility to depression and response to treatment (Wong et al, 2008). As 
expected due to their mechanism of action, clinical response to SNRIs and SSRIs is also 
influenced by genes that are not linked to monoaminergic neurotransmission (Uhr et al, 2008). 
Thus, polymorphisms of ABCB1, which is involved in drug transport across the blood-brain 
barrier, have an influence on the brain concentrations of antidepressant drugs thus determine 
the response to treatment (Uhr et al, 2008).  
3.8 Controversies in antidepressant therapy 
 
Over the past few years, there has been considerable debate as to the efficacy of 
antidepressants compared to placebo. In 2008, Irving Kirsch and colleagues published a meta-
analysis which stated that for a majority of patients, the difference in clinical improvement 
between the SSRI antidepressant drug and placebo was not significant. However, despite 
increased compliance, new drugs did not surpass the efficacy of some tricyclic drugs such as 
clomipramine (Danish University Antidepressant Group, 1986, 1990).   He stated that their data 
does indicate a small advantage for drug over placebo that is statistically significant only for 
major depressive disorder but had no effect on Moderate depression (Kirsch, 2008).The results 
of the meta-analysis showed that patients with moderate depression receiving placebo 
recovered just as well as the patients receiving medication did. This brought into question the 
efficacy of antidepressants, which have been used for over fifty years prior to the publishing of 
this meta-analysis. From the results of the meta-analysis, Kirsch concluded that SSRIs offer no 
advantage over placebo, antidepressants do not affect the long term outcome of depression and 
suicide, and that current recommendations on antidepressant prescribing should be 
reconsidered due to their benefits compared to risks.  
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There have been clinical trials with a chosen sample patients population that have shown 
remission and response rates of 40% and 60% respectively when treated with the standard 
antidepressant drugs which includes SSRIs and TCAs (Tollefson and Holman, 1994; Thase et 
al, 2001). In contrast to this finding however, naturalistic studies such as the Sequenced 
Treatment Alternatives to Relieve Depression (STAR*D) show a bleaker result that is less 
promising with remission and response rates of 30% and 50% respectively after treatment with 
citalopram (Artigas, 2015). The results of this finding from real patients have indicated that a 
large amount of patients that have been diagnosed with depression that are receiving standard 
antidepressant therapy have just showed partial responses therefore, these patients require 
further treatment with lithium, atypical antipsychotics or additional treatment such as 
electroconvulsive therapy (Carvalho et al, 2009; Mayberg et al, 2005). One of the most well 
known limitations antidepressant therapy is that their clinical action is slow to show an effect on 
the patient. This often raises doubt as to their efficacy among patients thus causing a decrease 
in patient compliance. The efficacy figures shown above is that which is typically shown in 6 to 8 
week periods, this is when antidepressant drugs begin to show a difference from placebo 
treatment.  
 
In contrast, it has been shown that 39% of patients do reach remission (defined as a score of ≤7 
on the Hamilton Rating Scale for Depression or ≤10 on the Montgomery–˚Asberg Depression 
Rating Scale) after eight weeks of antidepressant therapy (Kennedy, 2006). Another study 
showed that all antidepressants were superior to placebo regardless of the outcome measures 
applied (Delini-Stula et al, 1995). Compared to placebo, TCAs have been found to have a 
greater efficacy in the short term treatment of major depression (Storosum et al, 2001).  
 
 Antidepressants were also shown to have a greater effect on moderate and severe depression 
than placebo did (Vöhringer and Ghaemi, 2011).  However, though the effect that 
antidepressants have on depression is evident, a lot of consideration has to be given to the risk 
to benefit ratio of using them. Antidepressants commonly carry the risk of developing side 
effects such as sedation, apathy, fatigue, weight gain, nausea and sexual dysfunction along with 
the beneficial therapeutic effects.  
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Chapter Summary  
 
The etiology of depression is a topic that has been investigated for decades. The causes have 
often been linked chemical imbalances within the brain. Diagnosis of depression is made based 
on certain criteria from a manual known as the DSM-V. Treatment of depression is not only 
dependant on drugs in the form of antidepressants but also on therapeutic sessions with a 
psychiatrist. Drugs used in the treatment of depression have been developed following years of 
research into finding novel ways to treat the condition. The different classes have different 
modes of action. The three main classes used are SSRIs, SNRIs and TCAs.  
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Chapter Four: Method 
4.1 Study Site 
 
The Charlotte Maxeke Johannesburg Academic hospital (CMJAH) has a specialized out-patient 
psychiatric clinic which operates on a Wednesday and Friday. The psychiatric out-patient clinic 
at the hospital was purposively selected from all public sector academic sites in Gauteng since 
at this clinic there is an adequate patient load to provide sufficient prescriptions for the study.  
This clinic offers treatment to patient with numerous psychiatric disorders such as MDD, Bipolar 
disorder, psychosis, anxiety disorders and schizophrenia. Approximately 100 patients attend 
this clinic per week of which 40 are patients that are being treated for anxiety or depressive 
disorders. The orderly functioning of the clinic by appointment as well as the records of patients 
being treated by the psychiatric out-patient clinic been kept on site had allowed for convenient 
collection of the data from the records. Patient records from January 2011 to September 2014 
were included in the study. All the patient records that were used were of patients who were 
currently attending the clinic for treatment. The inclusion criteria was: 
 Patients were over the age of 18 years 
 Attended the clinic for treatment 
 Received prescriptions for antidepressants 
No patients receiving antidepressant therapy were excluded from the study.  
4.2 Sample Size 
 
Prior to obtaining the permission from the CEO, a sample size had to be calculated. For the 
purposes of this study, the required sample size of 1535 prescriptions was calculated (Epi-Info 
version 7), using a confidence level of 99% and a confidence interval of 0.025. A sample size 
was calculated to determine the number of prescriptions it was necessary to survey in order to 
produce results sufficiently powered to derive conclusions. Patients who had been visiting the 
clinic for treatment of MDD and GAD were included to measure the use of antidepressants. All 
other records had been excluded.  
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Z ² x (p) x (1-p) 
   ss =    c ² 
     2.58 x 0.5 x (1-0.5) 
   ss =    0.025 
Where: 
Z = Z value eg 1.96 for 95% confidence interval 
P = percentage picking a choice, expressed as a decimal (0.5 used for sample size needed) 
C = confidence interval, expressed as a decimal 
 
4.3 Ethics  
 
Permission to use patient records was also obtained from the head of the unit as well as the 
CEO of the hospital (Appendix B) 
Permission to conduct the study was obtained from the Human Research Ethics Committee 
(Medical) of the University of the Witwatersrand (M130654) (Appendix A). 
The Ethics committee approved the study in the condition that the identity of the patients used 
will be protected as a part of respecting their privacy. The patients’ anonymity was protected by 
using unique study specific patient numbers instead of patient names. No patient names were 
recorded on the case report forms, only study patient numbers. The links between study 
generated (coded) data and identifiable (patient) data was kept in a password protected file on a 
computer located in the department of pharmacology, with access only to the researcher and 
supervisor.  
4.4 Data collection 
 
The clinic makes use of an appointment book which is used to maintain order of appointments 
with between the doctors on duty and the patients. The patient numbers of patients attending 
the clinic for depression and anxiety were obtained using this book. Patient numbers were 
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chosen according to the ICD code. Patients with a diagnosis of anxiety, MDD and a mixed 
diagnosis were purposively chosen. The following ICD codes that were included are in Appendix 
D. 
Each ICD code had been included in the file, either alone or in combination. All patients using 
antidepressants had been included in the study. Concomitant drugs captured to provide a more 
complete picture of drug usage of patients. 
 
Once the files were obtained, the information of each prescription in the patient file was then 
recorded on the data collection sheet. In order to reach the calculated sample size of 1536 
prescriptions, it was necessary to record prescription data from January 2011. Information that 
was extracted from records: 
 Date of prescription 
 Race 
 Gender  
 Age 
 Marital status  
 Employment status  
 ICD-10 Code (diagnostic notes)  
 Drug name  
 Drug dose  
 Dosage instructions 
 Concomitant drug information 
 
4.5 Data Analysis 
 
Data abstracted on to case report forms was then captured on a purpose-designed spread 
sheet using Microsoft Excel 2010. The DDD of each indication for which each antidepressant is 
prescribed was tabulated according to the literature and  the actual PDD of each prescription 
was calculated and compared with the DDD. Each dose of every antidepressant used was 
recorded. In order to get the PDD of each antidepressant had been calculated as the average of 
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each antidepressant prescribed. This was then compared with the international guidelines of the 
DDD.  
For the purposes of this study, the statistical analysis program STATA version 13 was used.  
The data had then been analyzed according to the objectives which had been set. The patient 
demographics were the first variables to be analyzed. Data was coded (as per appendix 3) and 
loaded into the programme. Chi-squared tests were run to see if there were any statistically 
significant associations between patient variables and type of antidepressant chosen.  
 In order to describe the characteristics of the patient population, descriptive statistics such as 
means, frequency of use, frequency tables, proportions and ratios were used. When operating 
on the data statistically, confidence level of 99%, a confidence interval of 0.025 were used and 
the p-value was considered significant if less than 0.05. 
 
Logistic regression was used to determine variance between antidepressant prescribed, 
demographic factors as well as the duration of treatment. This was also done to determine if 
there is an association between diagnoses. All of these tests were recommended by a 
statistician according to previous drug utilization reviews which had used the same tests to 
measure the use of antidepressants. 
 
4.6 Costing 
 
The Pharmacy tariff is applied when medicines are dispensed based on a prescription. The 
charge for a medicine is comprised of the itemized cost as well as the facility fee that is levied 
per prescription. All of these items on the national tender are included in the list of charges that 
is circulated by the department of health. The facility fee is fixed according to the level of the 
facility. In the case of the Charlotte Maxeke Johannesburg Academic Hospital, every 
consultation is charged at R40.00, this fee is inclusive of the pharmacy tariff. 
 All medicine costing in South Africa are controlled through the single exit price (SEP) 
mechanism which lists the only price  that a medicine can be charged at. The cost of treating a 
patient with antidepressants can be measured using the prescription data obtained then 
calculating the cost using the single exit pricing and the pharmacy tariff as listed by the 
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department of health and released on specific dates (SA, 2009). In the public sector, the 
medicine is priced according to the contract price which is awarded by a tender.  
 The number of tablets used, taking dose into consideration, was multiplied by the date-
appropriate single exit price to derive a unit cost. In South Africa, the single exit price (SEP) is 
the maximum price which a medicine is allowed to be charged at. In the public sector, 
medication is priced according to the contact price by which a company supplies the medicine 
based on a tender contract.  Prices of each antidepressant were used according to prices from 
invoices in the pharmacy. The prices used was from the year 2014 and had been used as a 
guideline for the pricing of the study period.  
Chapter Summary 
The study site and methods used to conduct the retrospective drug utilization review had been 
stated. The costing of each antidepressant was calculated according to the tender price list.  
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Chapter Five: Results 
 
5.1 Patient Demographics 
 
5.1.1 Gender 
 
At the Charlotte Maxeke Johannesburg Academic hospital, patient prescriptions were recorded 
from January 2011 till September 2014. The total number of patients being treated with 
antidepressants at the psychiatric out-patient department, during that time, was 135. The total 
number of prescriptions that were recorded and analyzed was 1606. The patient population 
consisted of 41 male (30.3%) and 94 female patients (69.7%).  
 
Figure 5.1.1: Gender composition of the patient populationThe patient population which 
consists of 69.70% female and 30.30% male patients. 
The proportion of males to females was 1: 2.3 (standard error= 0.40), with a 99% confidence 
interval [0.57, 0.77] for females and [0.22, 0.43] for males. This means that for each patient that 
visited the facility, there had been more than twice that number who were females. 
Male Female
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5.1.2 Patient Ethnicity 
 
The population consisted of various ethnicities of which 35.70% (N=48) were Black, 10.30% 
(N=14) were Colored, 13.30% (N=18) were Indian and 40.70% (N=55) of which were White.  
 
Figure 5.1.2: Ethnicity composition of this group of patients. The patient population 
consisted of mostly of White patients (40.70% followed by Black patients (35.70%) the Indian 
(13.30%) and Colored (10.30%). 
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5.1.3 Ethnicity and gender 
 
The number of black male and female patients had been nearly equal with white patients having 
been composed of more females than males. For coloured and Indian patients, there had been 
more males than female patients.  
 
 
Figure 5.1.3: The comparison of ethnicity and gender. A comparison of the various ethnic 
groups with gender shows there were higher amounts of female patients for white and black 
groups whilst there were more males in the coloured and Indian groups. 
 
 
5.1.4 Age 
 
The average age of all the patients was 50.16 years (SD= 16.32). The sample patient 
population had consisted of 1.48% of patients who were under the age of 20 years. More than 
two thirds of this population was adults whose ages had ranged from 20 to 59, with a 
contribution of 71.30% of the total patient sample group. Patients aged 60 and over formed the 
remainder of the patient population with 27.22%. The patients were grouped into the three major 
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age groups in order to compare the use of antidepressants across various patients. By dividing 
the ages into three main groups, it allows for a clear comparison to be made between young 
adults and adolescents that are grouped as under 20s, adults and the elderly, since these age 
stratifications may have translated to clinical consequences with prescribing preferences.  
Table 5.1.1:Percentage of patients according to age groups. . The age groups are divided 
into the three main categories namely under 20, 20-59 and 60 and over to compare the use 
between each major phase of life 
Age Groups Percentage (%) 
under 20 1.48 
20-59 71.30 
60 and over 27.22 
 
 
Figure 5.1.4: grouping of patients according to age intervals. The amount of patients in 
each age group is represented showing the 55-59 age group as the one with the most amount 
of patients. 
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The big category of ages 20-59 was divided into smaller categorical age groups in order to 
refine the usage statistics and potentially identify any prescribing patterns. 
The majority of patients were aged between 55-59 followed by patients aged between 50 and 
54 (21,00% and 11.80% respectively).  
 
 
5.1.4.1 Age and gender comparison 
 
For patients aged 20-30, there had been a higher percentage of males compared to females. 
The same trend had followed in the 31-40 age group. However, there had been a higher 
percentage of females in the 51-60 age groups as well as the over 60 age group.  
Table 5.1.2: a gender comparison is shown across the various age groups. 
Age groups Female Male 
Under 20 2.38% 0.00% 
20-30 11.90% 26.31% 
31-40 14.28% 18.42% 
41-50 9.52% 10.52% 
51-60 34.52% 23.68% 
Over 60 27.38% 21.05% 
 
 
5.1.5 Employment status 
 
As a part of the patient demographic, the employment status of patients was also recorded. 
Unemployed patients consisted of 50.40% of the patient population whilst only 23.70% of 
patients were employed and the remainder was pensioners (25.90%).  
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Figure 5.1.5: The patient population as divided with regard to employment status. The 
employment status of the patient population is shown with most as the patients listed as 
unemployed.  
The employment status was recorded according to the information recorded on the patients file. 
It had not taken into account part time workers or those with informal employment, it was simply 
recorded on the basis of whether the patient considered themselves employed or not at the time 
of the study.  
5.1.6 Marital Status 
The marital status of patients was also recorded as a part of the patient demographics. Married 
patients consisted of 54.81% of the sample whilst single, widowed or divorced patients were 
45.19%.  
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Figure 5.1.6: Marital status of the patient population. Patients, who are single, divorced or 
widowed shown as being less than the married patients.  
5.1.6.1 Marital status and gender comparison 
 
The percentages of female and male patients who are married and single were relatively similar 
for both groups.  
 
Figure 5.1.7: Marital status and gender comparison. Married female patients were the 
largest group to have received a prescription for antidepressants. 
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5.2 Diagnosis 
 
Of the 135 patients attending the psychiatric out- patient clinic, the ICD 10 codes which are 
used when identifying the patients’ diagnosis had been recorded. More than half of the patients 
had been diagnosed with major depressive disorder or MDD (62.29%). Second to this had been 
patients with generalized anxiety disorder (GAD). Patients who had also been receiving 
treatment for a bipolar mood disorder had also been receiving antidepressant therapy (11.48%). 
Mild depression and MDD with psychotic features were the least present diagnosis (0.82% and 
4.92% respectively). 
Table 5.2.1: Percentage of patients with each represented diagnosis. Most patients had 
been diagnosed with major depressive disorder (MDD) followed by MDD with features of a 
generalized anxiety disorder (GAD), the least common diagnosed disorder had been that of mild 
depression. 
 
Diagnosis Percentage of patients (%) 99% confidence interval 
MDD 62.29 0.45-0.67 
 GAD 14.75 0.07-0.23 
MDD and psychosis 4.92 0.01-0.12 
Mild depression 0.82 0.005-0.94 
MDD and epilepsy 5.74 0.02-0.13 
MDD and Bipolar disorder 11.48 0.05-0.19 
 
5.2.1 Diagnosis and antidepressant use 
 
The type of antidepressant prescribed had been shown to have been influenced significantly by 
the ICD 10 code or diagnosis (p<0.0001) as shown in a Pearson Chi-squared test. 
Table 5.2.2: Diagnosis and antidepressant prescribed. The diagnosis of a patient had an 
association with the type of antidepressants prescribed. The use of the three groups of 
antidepressants is shown in relation to the diagnosis made. 
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Diagnosis Fluoxetine (N) Citalopram (N) Venlafaxine (N) 
MDD 11 40 25 
GAD 3 10 5 
MDD and psychosis 3 1 2 
Mild depression 0 0 1 
MDD and epilepsy 2 4 1 
MDD and Bipolar 
disorder 3 8 3 
        
Total 22 63 37 
 
5.2.2 Diagnosis and patient factors 
 
The types of patient factors that may influence the diagnosis had been analysed using the chi 
squared test to determine if there had been any statistically significant relationship. The patient 
demographic which correlated with the diagnosis was race (p=0.008). This was determined 
using the Pearson chi-squared test. 
Table 5.2.3: Comparison of diagnosis and ethnicity. When comparing the diagnosis among 
the ethnic groups represented in the study, it is shown that white patients were more frequently 
diagnosed with MDD and Bipolar disorder than any other group whilst black and Indian patients 
mostly received antidepressants for MDD. 
Diagnosis Black White  Coloured Indian 
MDD 31 27 4 14 
GAD 6 9 2 1 
MDD and psychosis 1 4 1 0 
Mild depression 0 0 1 0 
MDD and epilepsy 3 3 0 1 
MDD and Bipolar 
disorder 1 11 2 0 
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Pearson chi² (18)= 35.48; p= 0.008 
Of the total of 1606 prescriptions which had been the repeats for the 135 patients, 672 had been 
for citalopram, 560 had been made for venlafaxine, 259 for fluoxetine. The mean dose for each 
antidepressant is shown in section 5.3. 
 
 
 
 
 
58 
 
Chi-squared tests
 
          Pearson chi2(9) =  16.9539   Pr = 0.049
     Total          22         63         37         13         135 
                                                                   
         4           2          2          4          0           8 
         3           1          1          4          0           6 
         2           8         29          5          5          47 
         1          11         31         24          8          74 
                                                                   
   MSTATUS           1          2          3          4       Total
                                 AD
. tabulate MSTATUS AD, chi2
         Pearson chi2(18) = 145.5831   Pr = 0.000
     Total          22         63         37         13         135 
                                                                   
         7           0          0          0         13          13 
         4           3          8          3          0          14 
       1.6           2          4          1          0           7 
       1.5           0          0          1          0           1 
       1.3           3          1          2          0           6 
       1.2           3         10          5          0          18 
         1          11         40         25          0          76 
                                                                   
       ICD           1          2          3          4       Total
                                 AD
. tabulate ICD AD, chi2
          Pearson chi2(9) =  29.8003   Pr = 0.000
     Total          22         63         37         13         135 
                                                                   
         4           3          3         10          2          18 
         3           1          7          2          2          12 
         2           8         24         22          1          55 
         1          10         29          3          8          50 
                                                                   
      RACE           1          2          3          4       Total
                                 AD
. tabulate RACE AD, chi2
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5.3 Use of antidepressants 
 
Throughout the duration of the study, there had been three antidepressants that were 
prescribed. These antidepressants were the SSRIs fluoxetine and citalopram as well as the 
SNRI venlafaxine. 
Table 5.3.1: Dosing of each antidepressant. The frequency (number of prescriptions) of 
which each antidepressant is prescribed is shown along with the mean dose of each. 
 
Antidepressant Mean Dose(mg) Range (mg) Standard dev. Frequency 
Fluoxetine 35.45 20-60 16.27 259 
Citalopram 29.51 20-60 12.37 672 
Venlafaxine 239.18 75-300 63.33 560 
          
Total prescriptions       1491 
          
 
Table 5.3.1.1: The PDD and DDD of each antidepressant. 
Antidepressant PDD(mg) DDD(mg) 
Fluoxetine 35.45 20 
Citalopram 29.51 20 
Venlafaxine 239.18 150 
          Pearson chi2(6) =  12.7194   Pr = 0.048
     Total          22         63         37         13         135 
                                                                   
         3           8         17          6          4          35 
         2           5          8         14          5          32 
         1           9         38         17          4          68 
                                                                   
OCCUPATION           1          2          3          4       Total
                                 AD
. tabulate OCCUPATION AD, chi2
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Of the total patient population, almost half had been prescribed citalopram as their 
antidepressant (51.61%), followed by venlafaxine (30.33%) then fluoxetine (18.03%).  
Table 5.3.2: Amount of each antidepressant prescribed. The most commonly prescribed 
antidepressant was citalopram. 
Antidepressant type Percentage (%) CI - 99% 
Fluoxetine 18.03 0.09-0.26 
Citalopram 51.64 0.35-0.58 
Venlafaxine 30.33 0.18-0.38 
 
5.3.1 Dosing of antidepressants 
 
The most commonly prescribed antidepressant, as mentioned previously, had been citalopram. 
The 20mg form of this drug had been the most frequently prescribed dose. Eventhough 
venlafaxine had been prescribed to a lesser extent, the 225mg form of the drug had been as 
widely prescribed as the 40mg dose of citalopram.  
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Table 5.3.3: Antidepressants with their respective doses and the percentage of patients 
on each antidepressant. The dose of each antidepressant prescribed is shown along with the 
percentage of patients to which these antidepressants were prescribed, the most common of 
which being the 20mg citalopram. 
Antidepressant  Dose Patients using AD (%) 
Fluoxetine 20mg 8.19% 
  40mg 5.74% 
  60mg 4.09% 
Citalopram 10mg 1.64% 
  20mg 25.41% 
  30mg 7.38% 
  40mg 13.11% 
  60mg 4.10% 
Venlafaxine 75mg 1.64% 
  150mg 3.28% 
  225mg 13.11% 
  300mg 12.29% 
 
 
 
 
 
 
 
 
 
 
 
5.3.2 Antidepressants and gender 
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The type of antidepressant used was recorded for the patient population. 
Table 5.3.4: Antidepressant and gender comparison. Use of antidepressants across gender 
groups is shown to compare the most commonly prescribed type with a gender perspective 
  Fluoxetine (%) Citalopram (%) Venlafaxine (%) 
Male 23.86 44.74 31.57 
Female 15.11 53.49 31.40 
 
As shown previously with the total patient population, most males and females had been 
prescribed citalopram, although it had been prescribed to 12.33% more of the female patients 
(Males: 44.74%; Females: 53.49%). Fluoxetine was however prescribed to a slightly greater 
extent to males than females (males: 23.86%; females: 15.11%). With regards to venlafaxine, 
the prescribing frequency among both males and females had been relatively similar (males: 
31.57%; females: 31.40%).  
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Figure: 5.3.1: Antidepressant use divided by the gender. The graph shows the greater 
extent to which citalopram and venlafaxine had been prescribed to female patients whilst 
fluoxetine had been the preferred antidepressant among male patients. 
 
 
 
5.3.3 Antidepressant use in various age groups 
 
As previously shown, the preferred choice of antidepressant was the SSRI citalopram. When 
the various age groups have been considered however, there were some exceptions to the 
general prescribing practice.  Fluoxetine had been used equally to citalopram in the younger 
than 20 age group. . Within the 20-24 group, a majority had been prescribed citalopram 
(77.78%) with the remainder of the group having received prescriptions for fluoxetine (22.22%), 
none of the patients in this group had received venlafaxine. A similar type of pattern is shown in 
the proceeding 25-29 age group except for an increase in the number of patients on fluoxetine 
and the addition of venlafaxine which is used for the first time compared to the previous age 
groups. The same type of pattern of prescribing had followed to the 30-34 and 35-39 age group 
with citalopram being the drug of choice. In the 40-44 age group, no patients had been 
prescribed fluoxetine, and interestingly the use of citalopram (40%) had been less than that of 
venlafaxine (60%). In the 45-49 age group citalopram and venlafaxine had been used in equal 
amounts (33.33% for all three). The use of citalopram and fluoxetine had been equal in the 65-
69 age group with venlafaxine emerging as the drug of choice in these patients. Venlafaxine 
had been preferred over fluoxetine and citalopram in patients aged above 75.  
From the age group 40-44 years and older, the use of venlafaxine had been more frequent than 
that of fluoxetine, in contrast to the previous age groups where they had either been preferred in 
nearly equal amounts or fluoxetine had been prescribed more frequently.  
Table 5.3.5: Antidepressant use in smaller age groups. The use of each type of 
antidepressant is shown in the various age groups with intervals of around five years. 
Citalopram dominates as the most frequently prescribed antidepressant among most age 
groups with the exception of the 65-69 group where venlafaxine is the common antidepressant. 
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Age groups Fluoxetine (%) Citalopram (%) Venlafaxine (%) 
less than 20 
                       
50.00  
                           
50.00                              -    
20 – 24  
                       
22.22  
                           
77.78                              -    
25 – 29  
                       
27.30  
                           
63.80  
                        
9.90  
30 – 34  
                       
14.30  
                           
41.40  
                      
14.30  
35 – 39  
                       
25.65  
                           
48.70  
                      
25.65  
40 – 44                               -    
                           
40.00  
                      
60.00  
45 – 49  
                       
33.33  
                           
33.33  
                      
33.33  
50 – 54  
                       
19.05  
                           
54.76  
                      
26.16  
55 – 59  
                       
13.09  
                           
48.82  
                      
38.10  
60 – 64                               -    
                           
63.63  
                      
36.36  
65 – 69  
                       
28.56  
                           
28.56  
                      
42.88  
70 – 74                               -    
                           
50.00  
                      
50.00  
0ver 75 
                       
25.00  
                           
25.00  
                      
50.00  
 
Although the Pearson chi squared test had shown that the type of antidepressant chosen is not 
influenced by patient age (p=0.810), the linear regression test had shown that an increase in 
age is associated with an increase in the use of antidepressants (b=0.015; p<0.001). The result 
of the t-test (t=3.58) had shown that our co-efficient (0.015) is statistically significant (standard 
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error=0.04; CI 95%= 0.07-0.24) the older the patient, the more likely they are to be prescribed 
an antidepressant.  
The results of an ordinal logistic regression test of antidepressant and age showed a statistically 
significant likelihood ratio (LR) of 12.80 and probability (p=0.0003). As shown with the linear 
regression test, an increase in age is associated with an increase in the use of antidepressants 
(b=0.36), but to a greater extent than the previous test (SE=0.010; CI 95%= 0.15-0.56).  
These tests were done after consultation with a statistician. They were done in order to 
determine which patient variables are related to the antidepressant prescribed and if there is an 
association between the two.  
 
5.3.4 Ethnic groups and antidepressant use 
 
The use of antidepressants among the ethnic groups of the patient population were tabulated to 
show the frequencies to which these antidepressants were prescribed in each group. 
Citalopram had been the preferred antidepressant in Black, Coloured and White patients 
(57.14%; 58.30% and 44.00% respectively). Venlafaxine had been prescribed to a much greater 
extent in the Indian population (55.60%). Fluoxetine had been prescribed more to Black patients 
than other race group with the same group having Venlafaxine prescribed to the least amount of 
patients. With Indian patients, an equal amount of patients had been prescribed fluoxetine and 
citalopram, as mentioned previously, this group had the most patients receiving venlafaxine 
therapy. In White patients however, an almost equal amount of patients had received citalopram 
or venlafaxine (44.00% and 40.00% respectively).  
The patient race has been shown to vary with the type of antidepressant chosen (p< 0.0001) 
Pearson chi2 (9)= 29. 80; pr<0.0001 
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Table 5.3.6: Ethnicity and the type of antidepressant chosen. This has shown to vary with 
each race group with Indians receiving the most venlafaxine prescriptions blacks being more 
likely than white or coloured to be prescribed fluoxetine. 
Ethnicity Fluoxetine (%) Citalopram (%) Venlafaxine (%) 
Black 25.87 (N=10) 62.57 (N=29) 11.55 (N=3) 
Coloured 13.86 (N=1) 63.86 (N=7) 22.26 (N=2) 
Indian  20.40 (N=3) 20.40 (N=3) 59.30 (N=10) 
White 14.77 (N=8) 44.62 (N=24) 40.61 (N=22) 
 
In addition to having an influence on the antidepressant prescribed as well as the diagnosis as 
mentioned previously, the patient race also has been found to correlate with the dose 
prescribed (p= 0.004).  
 
 
Figure 5.3.3: The use of antidepressants with the ethnic groups. The use of 
antidepressants among the four ethnic groups is shown to have varied greatly. Citalopram had 
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been the preferred choice of antidepressant for all races except Indians to whom venlafaxine 
had been prescribed to more patients.  
An ordinal logistic regression test showed that race had a statistically significant relationship 
with a likelihood ratio of 5.45 and a p value of 0.01. The coefficient was 0.38 (SE=.0165; CI 95% 
0.06-0.70). 
 
 
 
5.3.5 Employment factors in antidepressant use 
 
As part of the patient demographics factors such as their employment status had been recorded 
to help try and understand the various types of patient factors that may have an influence on the 
type of antidepressant chosen. The three groups which the patient population had been divided 
into were employed, unemployed (which included housewives and students) and pensioners.  
With employed patients, citalopram had been the most frequently prescribed (52.40%) followed 
by fluoxetine (26.66%) then venlafaxine (20.94%). With regard to unemployed patients, who had 
formed a majority of the patient population, as with the employed counterparts, citalopram had 
been the most frequently prescribed drug but to a greater extent of 57.86% compared to the 
52.40% of employed patients. In the unemployed group of patients, the second most frequently 
prescribed drug was venlafaxine (26.96%) followed by fluoxetine (15.19%). The trend of 
prescribing had deviated slightly with pensioners. In this group, the majority of patients had 
been prescribed venlafaxine (43.95%), in contrast to the previous two groups for which 
citalopram had been the most frequently prescribed. For pensioners however, the second most 
frequently prescribed drug in this population had been citalopram (25.00%). 
. 
Pearson chi2 (6)=12.71; Pr = 0.049 
When the chi squared test had been performed on this data set, it had shown that there was a 
correlation between employment status and antidepressant type that is prescribed. 
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Table 5.3.7: Employment status and antidepressant prescribed. The employment status of 
each patient is considered along with the type of antidepressant prescribed 
 
Employment Fluoxetine (%) Citalopram (%) Venlafaxine (%) 
Employed 
                             
26.66 (N=8)  
                   
52.40 (N=17)  
                     
20.94 (N=6) 
Unemployed 
                             
15.19 (N=9)  
                   
57.86 (N=38) 
                     
26.96 (N=17)  
Pensioners 
                             
20.84 (N=5)  
                   
30.21 (N=8)  
                     
48.95 (N=14)  
 
 
Figure: 5.3.4: Graph comparison of antidepressant prescribed and employment status. 
The prescribing pattern when the patient employment status had been considered showed 
venlafaxine had been the preferred drug when prescribing to pensioners (43.74%) whilst 
fluoxetine had been preferred after citalopram in employed patients. 
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5.3.6 Antidepressant use related to marital status 
 
Marital status had also been used to identify is this type of patient demographic has an influence 
on the type of antidepressant prescribed. As previously mentioned, a majority of patients were 
married at the time of data collection followed by patients who considered themselves as single. 
In married patients, the most frequently prescribed antidepressant was citalopram (45.49%) 
followed by venlafaxine (36.42%) and then fluoxetine (18.49%). Single patients had a slightly 
different pattern of prescribing with citalopram being prescribed to a greater extent (65.24%) in 
this group, followed by fluoxetine (20.56%). Patients who had identified themselves as 
divorcees had been prescribed venlafaxine (66.66%) more frequently than any other drug. 
Within this group of patients, fluoxetine and citalopram had been prescribed in equal amounts. 
Patients who had experienced the death of their spouse had also been prescribed venlafaxine 
more frequently (50.00%) with fluoxetine and citalopram used equally in these patients.  
The type of antidepressant chosen was shown to be influenced by the marital status of the 
patient (p= 0.048) 
Pearson chi2 (9)= 16.95; pr= 0.048 
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Table 5.3.8: Marital status and antidepressant prescribed. A comparison of the use of 
antidepressants with the marital status of a patient showed varied prescribing patterns, single 
patients had included patients who considered themselves as single as well as divorced or 
widowed patients. It shows the high preference of citalopram to a greater extent in single 
patients. 
 
Marital status Fluoxetine (%) Citalopram (%) Venlafaxine (%) 
Married 
                             
18.49 (N=11)  
                   
45.49 (N=31)  
                     
36.42 (N=24)  
Single 
                             
20.56 (N=8) 
                   
65.24 (N=29)  
                     
14.18 (N=5)  
Divorced 
                             
16.67 (N=1)  
                   
16.67 (N=1)  
                     
66.66 (N=4) 
Widowed 
                             
25.00 (N=2) 
                   
25.00 (N=2) 
                     
50.00 (N=4)  
 
5.4 Concomitant drug use 
 
The use of concomitant drugs has also been measured. The most commonly prescribed agents 
are anti-epileptic agents but can be used as anxiolytic and mood stabilizers. Among the other 
drugs that had been prescribed simultaneously with antidepressants were anti-psychotic drugs, 
systemic anti-histamines and drugs used in pain management.  
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Table 5.4.1: the most frequently prescribed concomitant drug  
  Active Ingredient % of patients no. of patients 
Anti-epileptics       
 
Valproic acid 10.65% 13 
 
Lamotrigine 15.57% 19 
 
Gabapentin 24.60% 30 
 
Clonazepam 39.34% 48 
 
Carbamazepine 4.92% 6 
Anti-psychotic       
 
Quetiapine 8.20% 10 
 
Risperidone 18.03% 22 
Systemic anti-histamine       
 
Promethazine 19.67% 24 
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Table 5.4.2: Patient demographic summary..  Female patients received more than two thirds 
of the prescriptions for antidepressants. Of all ethnic groups, white patients accounted for the 
most antidepressant prescriptions along with patients in the 20-59 age group. The unemployed 
and married were also majority groups in this patient population. 
Variable % or Mean (SD) 
    
Gender   
Male 30.30% 
Female 69.70% 
    
Patient Ethnicity   
Black 35.70% 
White 40.70% 
Coloured 10.30% 
Indian 13.30% 
    
Age Groups   
Under 20 1.48% 
20-59 71.30% 
60 and over 27.22% 
    
Employment Status   
Unemployed  50.40% 
Pensioner 23.70% 
Employed 25.90% 
    
Marital Status   
Married 54.81% 
Single 34.81% 
Divorced 4.44% 
Widowed 5.92% 
    
Diagnosis   
MDD 62.29% 
GAD 14.75% 
MDD and psychosis 4.92% 
Mild depression 0.82% 
MDD and epilepsy 5.74% 
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MDD and Bipolar disorder 11.48% 
    
Antidepressant type   
Fluoxetine 18.03% 
Citalopram 51.64% 
Venlafaxine 30.33% 
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5.5 Cost of Antidepressants 
. The cost of each antidepressant is shown according to prices supplied by the National Department of Health (NDoH) which shows 
the most expensive antidepressant to be venlafaxine 
 
 
Antidepressant  Dose 
Quantity used (amount 
x pack size) Cost per unit % of Patients using AD (N) Total cost 
Fluoxetine 20mg 30 x 20mg R6.32 8.19% (10) R63.20 
  40mg 60 x 20mg R12.64 5.74% (7) R88.48 
  60mg 90 x 20mg R18.96 4.09% (5) R94.80 
Citalopram 10mg 15 x 20mg R3.20 1.64% (2) R6.40 
  20mg 30 x 20mg R6.40 25.41% (31) R198.40 
  30mg 45 x 20mg R9.60 7.38% (9) R86.40 
  40mg 60 x 20mg R12.80 13.11% (16) R204.80 
  60mg 90 x 20mg R19.20 4.1% (5) R96.00 
Venlafaxine 75mg 30 x 75mg R39.65 1.64% (2) R79.30 
  150mg 30 x 150mg R73.54 3.28% (4) R294.16 
  225mg 
30 x 150mg + 30 x 
75mg R110.05 13.11% (16) R1760.80 
  300mg 60 x 150mg R143.90 12.29% (15) R2158.50 
              100.00% (122) Total   per month                                                                                                          R 5131.24 
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The most expensive antidepressant used had been venlafaxine with a total cost of R4291.46 
per month to treat the 37 patients who had been prescribed that type of antidepressant. Patients 
who had received venlafaxine had a greater return rate than the other antidepressants for 
repeats. The extent of which had been calculated to be up to 5 months more than the other 
antidepressants. The average cost of treating each of the 37 patients with venlafaxine R115.97 
per month. 
The most commonly prescribed dose for both fluoxetine and citalopram had been the 20mg 
which costs R6.32 and R6.40 respectively. The total cost of using fluoxetine to treat the 22 
patients had been R246.48 per month, with an average cost of R11.20 per patient per month.   
As mentioned previously, citalopram had been prescribed to a greater number of patients than 
any other antidepressant. The total cost of using citalopram was R592.63 per month. The 
average cost of treating each patient using citalopram was R8.11 per month.   
The following is the average number of repeats per patient from January 2011 to September 
2014: 
 Average number of repeats for patients on fluoxetine: 
259 prescriptions for fluoxetine/ 22 patients = 11.77 repeats 
Average number of repeats for patients on citalopram: 
672 prescriptions for citalopram/ 63 patients = 10.67 repeats 
Average number of repeats for patients on venlafaxine: 
560 prescriptions for venlafaxine/ 37 patients = 15.13 repeats 
The medicine possession ratio measures the percentage of time a patient has access to 
medication. This is used as a means of measuring the patient compliance to medication 
Medicine possession ratio (MPR) =    Total Days supply in period 
      Last fill date – First fill date + Last fill days supply 
The MPR ranged from 90% to 87.5% in this study.  
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5.6 Cost of concomitant drugs 
 
Table 5.6.1: Cost of concomitant drugs. The cost of each concomitant drug is shown with the 
cost per unit (one month of treatment) 
  Active Ingredient 
Average Cost per 
unit % of patients Total Cost 
Anti-epileptics         
Valproic acid 
 
R107.64 7.51% (13) R1399.32 
Lamotrigine 
 
R61.47 11.04% (19) R1167.93 
Gabapentin 
 
R128.88 17.44% (30) R3866.40 
Clonazepam 
 
R153.69 27.91% (48) R7377.12 
Anti-psychotic         
Quetiapine 
 
  5.81% (10)   
Risperidone 
 
R13.27 12.79% (22) R291.94 
Systemic anti-
histamine         
Promethazine 
 
R68.97 13.95% (24) R1655.28 
Pain Management         
Carbamazepine 
 
R31.47 3.48%(6) R188.82 
 
The cost involved in the use of concomitant drugs had been calculated as a means to 
demonstrate the total cost of treating a single patient at the clinic. The most expensive drug that 
had been prescribed was the antiepileptic clonazepam with a cost of R153.69 per unit. This had 
been the most frequently prescribed drug with 48 patients, resulting in a total cost of R7377.12.  
The cheapest drug used was the anti-psychotic risperidone, which resulted in a total cost of 
R291.94 for the 22 patients who had received treatment with the drug. 
 
 
 
77 
 
 5.7 Change of antidepressant 
Over the duration of the study, there had been just two patients who have had their 
antidepressants changed. One patient had been changed from citalopram to venlafaxine, whilst 
the other patient had been changed from fluoxetine to venlafaxine. Both patients were female 
and middle-aged.  
 
Chapter summary 
This study confirmed the findings of other drug utilization reviews with antidepressants being 
prescribed more to females than males. SSRIs have been the drug of choice for most patients. 
Patient factors as well as the choice of antidepressant were compared and the cost of per 
patient per prescription of each antidepressant was calculated.   
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Chapter Six: Discussion 
 
This study found a number of factors associated with antidepressant use, many of which are 
similar to the findings of other antidepressant DURs. Through the analysis of the prescriptions 
from the sample population, valuable information had been obtained on the types of patients 
seeking treatment for depression and anxiety disorder as well as the types of antidepressants 
used by each patient group. The way in which the antidepressants were prescribed as well as 
the patient factors that are associated with prescribing had also been determined using various 
statistical tests. This has been the first study to be conducted on antidepressant usage in the 
public sector. Other studies that were done in South Africa used a similar methodology with the 
exception that those records were from medical aid data from the private sector. This meant that 
whilst the previous studies had used computerized records, this study made use only of the 
paper records, as is available in the public sector, which does not use computer based records.  
A similar methodology was used for this study because it was the same type usage that was to 
be analysed.   
The DURs in South Africa measured varied types usage patterns with regards to 
antidepressants. While the basic descriptive statistics remained the same, the other DURs 
measured usage based entirely on the information that was available.  One South African study 
measured patient demographics such as age, gender, race, marital status, urban/rural location, 
employment status, as well as educational qualification (Tomlinson et al, 2009). This has been 
one of the only studies in South Africa that measured the patient demographics of depressed 
patients to such an extent. Most other studies have simply measured the age and gender of 
patients using antidepressants and then focused more on the classes of antidepressant 
prescribed. It was because of this lack of specific information on the patient population of 
patients using antidepressant that this study gathered the type of characteristics as listed 
previously.  
Truter and Kotze in 1997 compared the PDD with the DDD of SSRIs from a medical aid 
database with another study done in a similar manner with the exception of the study population 
which had focused on a sample of 98 adolescents and young adults (Kairuz et al, 2003). In this 
study the PDD and DDD was compared across the patient sample for per drug per patient. This 
study had a varied age group as opposed to the other studies which focused just on a particular 
age group.  All the South African studies showed that SSRIs were considered to be the drug of 
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choice for MDD and anxiety disorders (Truter, 2010; Kairuz et al, 2003; Truter and Kotze, 1997). 
The patient population characteristics of those using medical aid funded facilities and those 
using the public sector do vary considerably, the usage patterns in the latter mentioned groups 
has not been determined. This study was done as a means to add to the current information 
about the use of antidepressants.   
  
 
6.1 Gender 
6.1.1 There are more prescriptions for antidepressants for women 
 
The fact that there are a greater proportion of women to men who are depressed is one of the 
most widely documented finding in the epidemiology of depression. Within most studies, the 
proportion of women had been nearly double or one and a half times greater than that of men. 
In this study, the proportion of males to females was 1: 2.3 (standard error= 0.40), with a 99% 
confidence interval [0.57, 0.77] for females and [0.22, 0.43] for males. This means that for each 
patient that visited the facility, there had been more than twice that number who were females. 
As shown in a number of other studies, there are more female patients receiving antidepressant 
therapy than males. Other antidepressant drug utilization reviews that have used patient 
information from countries in Europe have reported the same findings where there had been 
more than 65% of the entire patient population consisting of females (Bauer et al, 2008; Aarts et 
al, 2014; Serna et al, 2010). The results of the Danish study aimed at investigating sick leave in 
patients with depression found similar results with 59.69% of the patient sample being female 
(Gasse et al, 2013). The same has been shown in the United States, only more so, with a 70% 
of the patient population on antidepressant therapy being females (Lin et al, 2011). The higher 
prevalence of depression in females than males can be directly linked to this as it is known that 
depression has been shown to be twice as likely to occur in women as in men (Rihmer and 
Angst, 2008).  
The results from the South African mental health and stress study shows that there were more 
females than males who had received treatment or sought medical attentions because the 
group consisted mostly of females (53.7%) (Tomlinson et al, 2009). In 2009, results from a 
private medical aid scheme in South Africa showed that of these patients 53.74% were female 
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(Truter, 2010).  Another South African study on mental health patterns had shown that women 
were more likely to seek treatment overall however, among 12-month cases there had been no 
significant gender differences for mood disorders (Seedat et al, 2009). This is largely so when 
the patient population has a variation of age ranges. It has also been shown those women of 
low-income and those that are living in low and middle income countries have been documented 
to be at a particularly high risk of developing depression (Bennet et al, 2004). 
There have been deviations in the proportion of male to female when younger age groups of 
children and adolescents had been studied for the off-label use of antidepressants, where the 
proportions are almost equal (Dorks et al, 2013) leading to research into the gender bias of 
depression occurrence into post-pubertal females (Jang et al, 2009).  
6.1.2 Females seek treatment more frequently 
 
One of the reasons why there are consistently more females found in depressed patient groups 
than males is because of the help seeking behavior of males which is considerably lower than 
that of females (Angermeyer et al, 2013). The common belief among the public regarding 
mental health problems has often being a subject of interest. This is largely because of the 
relationship to stigma about recovery. Mental disorders such as psychosis, schizophrenia and 
depression have often been related to increased stigma in the community as well as the 
decreased expectation of recovery (Read et al, 2014). The common view of the public, which 
has proven to be quite resilient, is that the treatment of depression should rather consist of a 
psycho-social treatment over a bio-genetic or pharmacological treatment approach (Hughes et 
al, 2011). This bias may have contributed to the larger number of prescriptions for females in 
this study. 
6.1.3 Gender roles in relation to depression 
 
One study has been conducted to compare the depressive symptoms in women in Asia and 
western countries, this study has shown that most older Korean women had reported been 
responsible for their domestic chores which is rarely or never shared with their husbands in 
addition, these women  have shown households that are mainly patriarchal dominated which 
has led to a strictly defined role of the women in households, this increased stress has been 
shown to be a cause of marital distress and depressive symptoms (Jang et al, 2009). In this 
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study, although no social information was recorded, the employment status of patients had been 
collected to show whether they are employed, pensioners or unemployed. 
6.1.4 Marital status and gender comparison 
 
The percentages of female and male patients who were married and single were relatively 
similar for both groups. One study had shown that there had been an almost equal percentage 
of women and men who had been considered single or married and that there had been a 
higher proportion of women than men who had been widowed or divorced (Strohschein et al, 
2005). There had been gender differences in depressive symptoms by age which were 
significant (p=0.016) when married men were compared to married women (Jang et al, 2009). In 
contrast, patients in Beijing and Shanghai had displayed higher depressive symptoms in men 
aged 50-70 years old who had been living without a spouse than those who had been married, 
whilst the marital status of women had not showed any significant relationship with depression 
(Pan et al, 2008).  This difference between patients in Western environments and these shown 
in Asian societies showing the gender differences in the health benefit of being married could be 
caused by the social and cultural environment of Asian societies which have strictly demarcated 
gender roles which places more emphasis and importance of the patriarchal roles (as 
mentioned above). One study had shown that the relationship between gender and marital 
status was statistically significant (p<0.001) which shows that there is a gender difference in the 
correlation of marital status with depressive symptoms (Jang et al, 2009). In the same study, 
men who had been divorced or separated had reported higher amounts of depressive 
symptoms than married men did across all age groups. The difference observed in men had not 
been shown in members of the opposite sex. The difference in the symptoms of depression 
observed across varied marital statuses had not been shown in women aged 75 years and older 
including women who had been separated, divorced or widowed (Jang et al, 2009).  
 
 
 
 
82 
 
6.1.5 Age and gender comparison 
 
For patients aged 20-30 and 31-40 years, there had been a higher percentage of males 
compared to females.. This showed that males in this sample may be more likely to suffer from 
a depressive episode at an earlier age than females. However, there had been a higher 
percentage of females in the 51-60 age groups as well as the over 60 age group. This trend 
shows that the onset of major depression occurs for females at a later age than males. As 
previously mentioned, epidemiological studies done on patients suffering from depression have 
consistently shown that there are more women than men patients receiving treatment. Most 
studies have described the ratio of women to men as 2:1. The differences in gender patterns 
had been shown only from patients from 11 to 14 years onwards (Kessler, 2003). This has 
raised interest into the role of sex hormones in the etiology of depression among women 
especially since women report changes in depressed mood associated with experiences that 
cause changes in sex hormones for example as with patients going through menopause who 
have to use hormone replacement therapy and those patients on oral contraceptives (Hunter et 
al, 1986). However, regarding pregnancy, there has been limited research which has been done 
to study the effects of pregnancy on the onset and occurrence of major depression which has 
instead found higher rates of depression among non-pregnant patients (Hunter et al, 1986). 
Researchers has shown that for women who are married, depressive symptoms has increased 
as age increased (B=0.02; p=0.043) (Jang et al, 2009). 
6.1.6 Antidepressants and gender 
 
The type of antidepressant used was recorded for the patient population. As shown previously 
with the total patient population, most males and females had been prescribed Citalopram, 
although it had been prescribed to 12.33% more of the female patients (Males: 36.60%; 
Females: 48.93%). 
Fluoxetine was however prescribed to a slightly greater extent to males than females (males: 
22%; females: 13.83%). In 1995, in a study on a SA medical aid database, of a total of 2117 
patients on fluoxetine, 72.8% were female and 27.2% were male (Truter and Kotze, 1997). 
Female patients (62.33%) were more frequently prescribed SSRIs and SNRIs than males (Van 
Schalwyk and Truter, 2010).  
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 With regards to venlafaxine, the prescribing frequency among both males and females had 
been relatively similar (males: 26.30%; females: 28.72%). Males had been prescribed 
amitriptyline slightly more than females (males: 12.10%; females: 8.51%). The most commonly 
prescribed antidepressant active ingredients were fluoxetine (13.92%), citalopram (14.09%), 
escitalopram (14.60%) and imipramine (19.77%) in this patient population where 814540 
antidepressants were prescribed of which 12549 had been prescribed to patients 18 and 
younger, of these patients 53.74% were female (Truter, 2010). In the current study, venlafaxine 
had been prescribed in nearly equal amounts among males and females. Citalopram was 
prescribed more to females than males whilst fluoxetine was prescribed more to males than 
females. 
 
The prescribing patterns of TCAs were studied using patients who are on a private medical aid 
scheme, data from 1996 (1982 patients) and 2002/2003 (2345 patients) were used (Truter and 
Kotze, 2006). Almost two-thirds of these patients were female (67.41% in 1996 and 57.53% in 
2002/2003) (Truter and Kotze, 2006). Interestingly, TCAs were more frequently prescribed to 
males than females in the younger age groups in 1996 but in the older age groups in 2002/2003 
(Truter and Kotze, 2006) this could be mainly due to the use of TCAs in pain management in 
recent times. 
 
6.2 Patient Ethnicity 
 
Differences in depressive symptoms as well as the prevalence of depression are found to vary 
among various ethnic groups. This patient demographic had been recorded in order to measure 
whether this type of variance is also evident in the patient population. Some studies have shown 
that the prevalence of depression is similar among ethnic groups eventhough there are 
differences in the treatment rates and diagnosis of patients (USDHHS, 2001). The results of 
these studies had shown that ethnic minorities are the least likely to seek or receive treatment 
for depression as well as the least likely to use specialized mental health facilities, in addition 
they also have longer delays before initiating treatment for depression compared to white 
patients in the US (Wang et al, 2005). The treatment preferences also varies between ethnic 
groups as well with Whites and Natives in the US preferring medication to counseling whilst 
Asians, Hispanics and African Americans preferring counseling to medication (Givens et al, 
2007).  
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One study has shown that there are differences in the type of depressive symptoms reported 
between Latino African-American and white patients with Latinos reporting more symptoms than 
either African-American or white groups (Kemp et al, 1999). Another study has also shown that 
Whites and African-Americans experienced the same amounts of depressive symptoms with 
Mexican Americans showing to have a higher level of depression compared to the previous two 
groups (Neff and Hope, 1993). Another study had shown that both the past year and lifetime 
prevalence of major depression varied between ethnic groups with the largest prevalence being 
found with Puerto Rican patients and the lowest found among Chinese and Filipino groups 
(Gondalez et al 2010). A similar type of study had reported the type of factors that may 
contribute towards a patients vulnerability to depression with regard to ethnicity, this study had 
shown that Hispanic patients were largely concerned with factors such as change in 
environment, control of events and affiliation to groups whilst whites were more concerned 
about issues that had been related to achievement and African-Americans were the least 
concerned with factors that related to intimacy (Bernsteinl, 1992). One study had shown that 
race or ethnicity differences in depression are mixed with results of some studies showing that 
the African Americans and Hispanics have reported lower rate of depression and symptoms of 
depression (Williams and Sternthal, 2010). Another study showing the differences of depression 
among individuals who had been incarcerated has shown that the greatest difference between 
depressed inmates had been due to their race (Roxburgh and MacArthur, 2014).  
 
The population in the current study consisted of various ethnicities of which 35.7% (N=48) were 
Black, 10.3% (N=14) were colored, 13.3% (N=18) were Indian and 40.7% (N=55) of which were 
White. In the United States, patients who were part of their patient population in that study, 86% 
were of Caucasian origin (Lin et al, 2011). Another US study showed that the duration of major 
depression diagnosis had been higher in Puerto Ricans, Mexican Americans and African 
Americans compared to Whites (Gondalez et al, 2010). 
Given the demographic of our country where South Africa consists of 76.4% Black, 9.1% White, 
8.9% Coloureds and 2.5% Indian or Asian (STATS SA, 2013), it is quite interesting to note that 
there were more White patients than Black patients who had sought treatment at the facility and 
more Indian than Coloured patients even though the demographics of South Africa as a whole 
shows that Coloureds are in a greater proportion to Indians. Also, in the public sector there is a 
85 
 
larger percentage of black patients as compared to the private sector. This contrasts the results 
of this study where there had been a greater percentage of white patients at this psychiatric 
facility.  Results from the South African stress and health study analysed 4351 adult South 
Africans of all ages and all racial groups. The sample of patients had been diagnosed with major 
depression (Tomlinson et al, 2009). The group consisted mostly black patients (76.2%) followed 
by coloureds (10.4%), white (3.4%) and Indian/Asian (3.4%). This shows a great variation from 
the results found at the Charlotte Maxeke Johannesburg Academic hospital with regard to the 
proportions of each racial group, this could be because of this study’s smaller sample size or 
due to the fact that the hospital is situated in a densely urban area to which mostly residents 
from Johannesburg or nearby surrounding areas attend the facility for treatment which reduces 
the chance of having patients from rural areas.  
We could attribute the lower level of Black patients to White patients in this sample group due to 
the type of help seeking behavior of Black patients.  A study conducted on 4351 adults across 
South Africa to show the help seeking behavior of patients with a mood or anxiety disorder had 
shown that black patients (OR=25, χ2=12.81, p=0.005) were more likely to have accessed the 
complementary and alternate medicine sector rather than seek help from a health professional 
(Seedat et al, 2009). With this is mind, it is easy to assume that the reason for not having a 
large amount of Black patients is due to the fact that Black patients would rather consult 
traditional healers or other forms of complementary medicine choices than visit a medical 
professional to seek advice and treatment. Diseases of a mental origin are often considered a 
spiritual matter among some cultures, including African traditions (Seedat et al, 2009). This 
helps to explain why Western and modern medicine is avoided to a certain extent in conditions 
such as depression because of the belief that these conditions have to be dealt with using 
traditional medicine or advice and remedies. Whites (OR=10.9) and coloreds (OR= 4.1) were 
more likely than blacks to have seen a psychiatrist and whites were found to be more likely than 
blacks to have used mental health services (Seedat et al, 2009). Studies have shown the varied 
beliefs of depression and its treatment between different ethnic groups with ethnic minority 
groups being less likely to believe that the cause of depression is a biological change (Givens et 
al, 2007). These same minority groups had also less faith in using antidepressants in the 
treatment of depression, they had been more likely to believe in non pharmacological treatment 
such as counseling and prayer as these patients felt that antidepressants were addictive 
(Givens et al, 2007). 
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One study that had been conducted using Medicaid patient information in the US had shown 
that the patient’s race had an influence on the type of antidepressant prescribed (Melfi et al, 
2000). The study had shown that of all those patients receiving antidepressant therapy, whites 
were found to be more likely than patients of an African descent to have been given SSRIs 
(Melfi et al, 2000). 
6.2.1. Ethnicity in relation to other patient factors 
 
In this study the amount of black male and female patients had been nearly equal with white 
patients having been composed of more females than males. For coloured and Indian patients, 
there had been more males than female patients. There have not been many studies which 
have been done to compare the rate of depression among race groups whilst comparing the 
gender factors of these patients as well. Most studies that compared gender differences had 
been primarily done in White patients.  
One study had shown a comparison of various patient factors such as age and gender with 
relation to a patient’s ethnicity. The ethnicities used in this study were Chinese, Filipinos, 
Vietnamese, Cubans, Mexican Americans, Puerto Ricans, black Caribbean Americans, African 
Americans and Whites, all of whom live in the United States. It had shown the variances 
between ethnic groups with regard to prevalence rates, age of onset, disability, treatment use 
and severity of depression. In this study, patients aged 18-24 were found to be more abundant 
in Mexican Americans than any of the other race groups. Mexican Americans had also shown 
the largest amount of patients aged 25-34 compared to every other ethnicity which had the 
majority of patients in the 35-44 age group. With regard to the relationship between gender and 
ethnicity, every race group had a larger percentage of female patients than males with the 
exception of Cubans, Mexican Americans Puerto Ricans and Caribbean Black Americans. The 
same study has shown that the age of onset of depression varied among foreign born and US 
born ethnic groups with Cuban and Puerto Rican groups showing a significantly earlier age for 
the onset of major depression. The odds of a major depressive episode occurring had also 
shown to vary between ethnic groups with Puerto Ricans, Mexicans and African Americans 
showing a significantly higher odds of having a recurrence compared to Whites (Gondalez et al, 
2010).  
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6.2.2 Ethnic groups and antidepressant use 
 
The use of antidepressants among the ethnic groups of the patient population had been 
tabulated to show the frequencies to which these antidepressants were prescribed in each 
group. Citalopram had been the preferred antidepressant in Black, Coloured and White patients 
(57.14%; 58.30% and 44.00% respectively). The patient race has been shown to be associated 
with the type of antidepressant chosen (p< 0.0001). 
 
In correspondence with the finding that race has been associated with the diagnosis and 
antidepressant chosen; race has also been found to have an influence on the dose prescribed 
to patients (p= 0.004). Black patients were more likely than any other group to receive a dose of 
20mg of citalopram and fluoxetine. White and black patients were prescribed 30mg of 
citalopram, 40mg of citalopram and fluoxetine and 75mg of venlafaxine with the same frequency 
however many more white patients had been prescribed the 60mg citalopram or the 225mg and 
300mg dose of venlafaxine ..  Coloured patients were more likely to receive a dose of 40 mg.  
 
6.3 Age groups in relation to depression 
 
The average age of all the patients was 50.16 years (SD= 16.32). The majority of patients were 
aged between 55-59 years followed by patients aged between 50 and 54 years (21% and 
11.8% respectively). This is higher than the results of the SASH study where the mean age had 
been 37.0 years (Tomlinson, et al, 2009). In certain European countries the average age of 
patients receiving antidepressant therapy had been slightly lower than shown here at 46.8 years 
(SD=14.7) (Bauer et al, 2008). In the Netherlands, researchers had used a patient population 
consisted of 14,926 patients who were receiving antidepressant therapy, which had shown that 
this group presented with the average age of 65.5 years (SD=10.5) (Aarts et al, 2014). One 
South African study done on a medical aid population showed that the average age of patients 
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on antidepressants were 53.4 years (SD= 14.5 years), the average age of the male participants 
was 54.0 years (SD=15.4 years) and the average of the female patients were 53.2 years 
(SD=14.2 years) (Truter and Kotze, 1997).  
 
 Interestingly, the use of antidepressants, which is measured by the composition of this patient 
sample, had been shown to increase with an increase in age with the exception of the 30-34 
years which showed close to a 3% decrease from the 25-29 ages whilst the 40-44 year age 
groups had shown a 6% decrease from the 35-39 range. A Danish study had reported similar 
finding with 10.53% in the 18-24 years age range, 21.01% in the 25-34 year range 27.10% in 
the 35-44 group with a slight decline in the 45-54 age range to 25.35%, however there had been 
a deviation in the 55- 64 group where the prevalence had decreased sharply to 16.0% (Gasse 
et al, 2013). The use of antidepressants was shown to be much lower for the 60-64 age group 
with a decrease of nearly 12% compared to the 55-59 years age patients. The increase in 
antidepressant use in the elderly age groups could also be related to increasing loneliness, 
physical health problems and other disabilities as well as the worsening of chronic diseases 
(Aarts et al, 2014; Parabiaghi et al, 2011). In order to compare the use of certain 
antidepressants over a time span, a local study using information from a medical aid database 
from the year 1996 and 2002/2003 showed the changing patient demographics of those who 
had been prescribed amitriptyline largely due to the fact that it is prescribed more frequently for 
pain management than depression (Truter and Kotze, 2006).  A large number of patients were 
in the age group of 40-69 years (67.51% in 1996 and 49.68% in 2002/2003) whilst there was a 
few patients younger than 20 years (3.79% in 1996 and 8.66% in 2002/2003) (Truter and Kotze, 
2006). In comparison the average age of patients in 1996 was 52.99 (SD=16.02) and 42.66 
(SD=16.48) in 2002/2003 (Truter and Kotze, 2006). Other studies have also shown similar 
patterns with regard to antidepressant use and age. In one study, the majority of patients 
(21.40%) were aged between 35 and 44, patients aged 18-24 had accounted for 15.00% of 
patients, with a slight increase to 16.20% in the 25-34 age group. The least amount of patients, 
6.60% belonged to the over 75 age group (Gondalez et al, 2010). 
 
 
Patients under the age of 20 had only accounted for 1.48% of the total patient population in this 
study. This sample had been from the psychiatric ward out-patients so that only patients treated 
for depression and anxiety or some form of bi-polar disease had been represented here. The 
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use of antidepressants is generally not recommended in children and adolescents due to the 
fact that they are more likely to develop a suicidal tendency on these drugs. There is a black 
box warning on the package inserts explaining this. The result of this warning has caused the 
diagnosis of depression and subsequent use of antidepressants in patients under the age of 18 
years; this conversely had been linked with an increase in suicide rates among children and 
adolescents (Courtet et al, 2014). A study in Germany measuring the use of antidepressants in 
children and adolescents for both depression and off-label uses showed that the prevalence of 
antidepressant use was 1.84 per 1000 children in 2004, 1.57 in 2005 and 1.66 in 2006 from the 
children treated with antidepressants, 56.30% had been diagnosed with a depressive disorder. 
(Dorks et al, 2013).   
 
6.3.1 Antidepressant use in various age groups 
 
As previously shown, the preferred choice of antidepressant is the SSRI citalopram. When the 
various age groups have been considered however, there were some exceptions to the general 
prescribing practice.   Fluoxetine had been used equally to citalopram in the less than 20 years 
age group. The off-label use of antidepressants in this age group of patients has often being a 
topic of investigation. In Germany, this type of antidepressant use had been investigated further 
using a patient sample that consisted of children and adolescents which showed that 
amitriptyline had accounted for a total of 7.39% of antidepressants prescribed within the group 
while fluoxetine consisted of 12.03% of prescriptions (Dorks et al, 2013). Interestingly, 
prescriptions for citalopram only contributed to 6.76% of the total antidepressants prescribed 
(Dorks et al, 2013). The SNRI venlafaxine had been prescribed to 1.54% of all the patients 
under the age of 17 (Dorks et al, 2013). A study to show the prescribing patterns in patients 
younger than 18 showed that SSRIs accounted for 55.91% of antidepressant prescriptions 
which was ahead only of TCAs which contributed to 32.32% of prescriptions. These two 
antidepressants accounted for 79.49% of the antidepressant cost (Truter, 2010). Another study 
which had aimed at investigating the prescribing patterns of SSRIs and SNRIs in patients 19 
and younger showed that 440 patients younger than 19 years receiving antidepressant therapy 
which had accounted for 6.20% of patients of any age receiving antidepressants (Van Schalwyk 
and Truter, 2010). The average age of these patients was 14.21 (SD=3.05) years with the 
majority of patients being older than 12 years old (77.13%) (Van Schalwyk and Truter, 2010). 
Antidepressants prescribed to patients 18 and younger, from a private medical scheme 
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database, 12549 antidepressants were prescribed to this patient population out of the total of 
814540 antidepressants prescribed in the year 2009 (Truter, 2010).  
With regard to the current study, within the 20-24 years range, an overwhelming majority had 
been prescribed citalopram (77.78%) with the remainder of the group having received 
prescriptions for fluoxetine (22.22%), none of the patients in this group had received 
venlafaxine. A similar type of pattern is shown in the proceeding 25-29 age range except for an 
increase in the number of patients on fluoxetine and the addition of venlafaxine which is used 
for the first time compared to the previous age groups. The same type of pattern of prescribing 
had followed to the 30-34 and 35-39 age range with citalopram being the drug of choice.  
In this study, the 40-44 age range, no patients had been prescribed fluoxetine, and interestingly 
the use of citalopram (40%) had been less than that of venlafaxine (60%). Fluoxetine had been 
used for the first time in the 45-49 age range which had shown an equal amount of use for 
citalopram and venlafaxine (33.33% for all three). From the 40-44 age range onwards, the use 
of venlafaxine had been more frequent than that of fluoxetine, in contrast to the previous age 
groups where they had either been preferred in nearly equal amounts or fluoxetine had been 
prescribed more frequently. 
 
The use of citalopram and fluoxetine had been equal in the 65-69 age range with venlafaxine 
emerging as the drug of choice in these patients. Venlafaxine had been preferred over 
fluoxetine and citalopram in patients aged above 75. When the use of antidepressants is 
investigated in the elderly, higher age categories showed a higher prevalence of antidepressant 
use such as the age group of 72–77 years of age group use being 6.5% (SD = 0.8) and in 
elderly > 78 years of age group being 7.4% (SD = 1.7) when compared with the two lower age 
categories 45–64 year age group being 6.3% (SD = 2.3) and 65– 71 years age group being 
6.0% (SD = 1.3) (Aarts et al, 2014). The increase in antidepressant use in the elderly age 
groups could also be related to increasing loneliness, physical health problems and other 
disabilities as well as the worsening of chronic diseases (Aarts et al, 2014;Parabiaghi et al, 
2011). 
Although the Pearson chi squared test had shown that the type of antidepressant chosen is not 
influenced by patient age because of the high p-value (0.810), the linear regression test had 
shown that an increase in age is associated with an increase in the use of antidepressants 
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(b=0.015; p=0.001). The result of the t-test (t=3.58) had shown that our co-efficient (0.015) is 
statistically significant (standard error=0.04; CI 95%= 0.07-0.24). This shows that the use of 
antidepressants is likely to increase with an increase in age. 
The results of an ordinal logistic regression test of antidepressant and age showed a statistically 
significant likelihood ratio (LR) of 12.80 and probability (p=0.0003). As shown with the linear 
regression test, an increase in age is associated with an increase in the use of antidepressants 
(b=0.36), but to a greater extent than the previous test (SE=0.010; CI 95%= 0.15-0.56). 
6.4 Employment status in relation to depression 
 
Unemployed patients consisted of 50.4% of the patient population. Depression has often been 
associated with reduced productivity, work absenteeism (Gasse et al, 2013). This could be 
because of financial burdens and stress which have caused the depression or it could be as a 
result of lack of interest in work or absenteeism which could have caused a previously employed 
patient to become unemployed. This trend in depressed patients where they have taken long 
periods of sick leave is shown where among those with sick leave, nearly 67.8% had taken sick 
leave for longer than 8 weeks and 34.3% longer than a period of 26 weeks, this high rate of sick 
leave can be related to job losses because of the depression (Bratberg et al, 2009; Lund et al, 
2008). Other studies in South Africa had shown similar finding where 69.2% of the patients had 
been unemployed at the time of the study (Tomlinson et al, 2009).  
 
The high rate of unemployment could also be representative of the high rate on unemployment 
in South Africa however, in Europe a study showed that over various countries, only 13.7% of 
the patients were unemployed and 50.1% of the sample had been in paid work at the time of the 
study (Bauer et al, 2008). Only 23.7% of patients were employed in this study.  The remainder 
of the patient sample was pensioners (25.9%), this can be related to the age groups where 
there had been over 26% of the patients that were over the age of 59 years. It is clear that 
employment can be a major source of stress which does contribute to the aetiology of 
depression. Earlier findings have shown that there is no specific event which can contribute to 
major job stress instead it is an accumulation of a number of minor events in the workplace to 
which many individuals blame as the source of their discomfort at work (Iavovides et al, 2003). 
Jobs stress has been associated with changes in both physical and mental health.  
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The way in which patients have increased tendency to stay away from work is a well 
documented occurrence however; there have been few studies to document the sick leave 
patterns of patients during the course of taking antidepressants. In the US, researchers have 
found that before use of antidepressants, sick leave had been relatively high but then decreases 
after the treatment is initiated (Birnbaum et al, 2000). There have been a number of studies 
which have shown that the presence of mental illness had been linked with negative 
employment outcomes with a diminished ability to obtain and keep their employment (Adler et 
al, 2004; Cowell et al, 2009). Conversely, longitudinal studies have revealed that there is a clear 
relationship between unemployment and mental health which showed that there is a mental 
health benefit when patients move from unemployment to employment whilst there is a decline 
in the state of mental health when moving from employment to unemployment with these 
participants showing an increased likelihood to develop depressive symptoms (Murphy and 
Athanasou , 1999).   
 
6.4.1 Employment factors in antidepressant use 
 
When the chi squared test had been performed on this data set, it had shown the employment 
status influence antidepressant type that is prescribed. 
As part of the patient demographics factors such as their employment status had been recorded 
to help try and understand the various types of patient factors that may have an influence on the 
type of antidepressant chosen. The three groups which the patient population had been divided 
into were employed, unemployed (which included housewives and students) and pensioners.  
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6.5 Marital Status and depression 
 
Married individuals have been shown to enjoy longer lives due to their better mental and 
physical health compared to individuals who were non-married (Earle et al, 1998; Ross 1995). 
The positive mental health benefits of being married could be attributed to a number of reasons 
such as financial security due to the earning of the spouse, access to economic resources 
because some labor markets command higher wages for individuals who are married as well as 
the social support which is tendered for by spouses (House et al, 1988). However, recent 
studies have shown a clear association between depression and marital dissatisfaction 
(Whisman et al, 2004; Coyne et al, 2002).  
 
 
The marital status of patients was also recorded as a part of the patient demographics because 
in previous studies, the marital status had shown to be a predictor or have an influence on the 
depressive state as well as to a certain extent had an association with the types of 
antidepressant chosen (Bauer et al, 2008; Serna et al, 2010). In Denmark, 29.66% of patients 
receiving antidepressant therapy had been single whilst 58.75% had been married or living with 
a domestic partner. There is evidence of an association between marital status, divorce rate and 
depression (Merikangas et al, 1985). Studies have reported that rates of depression are higher 
among married women than non-married women (Gove, 1972), the rates of divorce are found to 
be greater in patients with a history of a mental disorder, and divorced patients were more likely 
to develop a psychiatric condition (Merikangas et al, 1985). Though early studies that had 
shown that women who are married more of a mental health vulnerability than non-married 
women because of their restricted roles and social isolation due to home and economic 
dependence on a male partner (Gove, 1972), these findings have been largely discredited or 
not supported with a number of other studies showing that the mental health benefits of being 
married has been equally found in both males and females (Ross, 1995; Kim and McKenry, 
2002; Simon, 2002). This confirms the finding in another study which showed that amicable 
marriage continues to be beneficial for the mental health of an individual (Strohschein et al, 
2005). 
 
Married patients consisted of 54.81% of the sample whilst single, widowed or divorced patients 
were 45.19% in this study. The finding that more than half of the patient sample in a population 
that had been receiving antidepressant therapy is consistent with other studies in Europe where 
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56.8% of the patients studied were married or living with a domestic partner (Bauer et al, 2008) 
and the same pattern is shown in local studies for which more than half of the patients had been 
married at the time (Tomlinson et al, 2009). This finding can, bring into question the numerous 
studies which have shown that the benefits of marriage are positive for both mental and physical 
healths with married individuals showing lower rates of depression than those who are single, 
divorced or have been widowed (Williams 2004; Afifi et al, 2006; Inaba et al, 2005). However, 
no research was undertaken in this study on the state of the marriage (just of its existence) and 
so it may be that the marriage contributed to loss of resilience on our participants.  
 
Patients who were divorced accounted for the least amount of patients with 4.44%, followed by 
widowed (5.92%). This finding could be attributed to the fact that some studies have shown 
patients who have been widowed for a long time do not show more signs of distress than those 
who are continuously married (Umberson et al, 1992). This supports the theories which show 
that the initial stress caused by bereavement tends to have less of an effect on the 
psychological well being of an individual the more time passes from the time of bereavement 
(Strohschein et al, 2005). More than one third of the patients had considered themselves as 
single (34.81%).  
There was a correlation between type of antidepressant chosen and type of the marital status of 
the patient (p= 0.048) in this study however, there are little current studies that have been done 
which compares the use of antidepressants with regard to the type of antidepressant chosen. 
6.6 Patient Diagnosis 
 
As a means of standardizing diagnosis of patients across various health facilities throughout the 
world, a set of codes which cover types of diseases, abnormal findings, symptoms and signs, 
social circumstances as well as complaints for causes of injury or disease was developed. This 
code is known as the ICD 10 codes which are the 10th revision of the International statistical 
classification of diseases and related health problems (WHO, 2007). The ICD code classification 
is considered one of the oldest as well as the most supported classifications in illness. It is of 
great use for record keeping purposes because it is a standardized system that uses numeric 
nomenclature as a means for identification of patient’s illnesses. The system had been criticized 
for not being suitable in cases where little or no information is available about the patient and 
where they have to be classified based on the symptoms.  
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F00-F99 is used to identify mental and behavioral disorders. The ICD codes for mental and 
behavioral disorders covers extensive conditions as well as their subdivisions so that a precise 
diagnosis can be made as well as to guide the kind of treatment to which a patient is prescribed. 
The code covers a range of conditions that include dementia, schizophrenia, bipolar disorder, 
depressive disorder and a range of anxiety disorders and phobias. Patient records with following 
diagnosis were included in the sample: MDD, GAD, MDD with psychotic features, Mild 
depression, MDD with epilepsy and MDD with Bipolar disorder (BPD).  
 
The ICD 10 codes which are used when identifying the patients’ diagnosis had been recorded. 
More than half of the patients had been diagnosed with major depressive disorder or MDD 
(56.30%).  Second to this had been patients with MDD showing features of a generalized 
anxiety disorder (GAD) which had accounted for 13.3% of the sample patient population 
diagnosis. Antidepressant and anxiolytic medications are often used to treat anxiety or 
depression in the general population. This is much lesser than that shown in a drug utilization 
review which showed that 51.1% of all patients, in a sample that represented various countries, 
had received antidepressant treatment for an anxiety disorder (Bauer et al, 2008).  
Patients who had also been receiving treatment for a bipolar mood disorder had also been 
receiving antidepressant therapy (10.37%). Mild depression and MDD with psychotic features 
were the least present diagnosis (0.74% and 4.44% respectively).  
. 
6.7 Prescribing 
 
In South Africa, the primary health care facilities ensure that treatment is standardized by using 
treatment protocols for mental disorders in order to encourage a better mental health for 
patients with these disorders as well as a useful practical guide for health care providers to be 
able to effectively manage these psychiatric disorders across both the district and the 
community levels (Burn et al, 2007). These protocols are in accordance with the Standard 
Treatment Guidelines and the Essential Drug List (EDL). The medicines that are listed in these 
guidelines and the drug list include anxiolytics, antidepressants, antipsychotics, mood stabilizers 
and antiepileptic drugs which are prescribed according to the diagnostic ICD-10 code that each 
patient is assigned. These lists, guidelines as well as the drugs are made readily available at 
96 
 
hospitals where patient with these mental disorders are being treated. These protocols and 
guidelines are to assist non-psychiatric health care providers such as medical officers and 
psychiatric nurses who are involved in the daily care and management of patients who use their 
facilities not only per province but throughout the public health care system in South Africa 
(Burns et al, 2007). The use of the essential drug list and these treatment guidelines are in 
accordance with the WHO recommendation that where there is a policy of community mental 
health care and its integration into general health services, essential drugs must be made 
available at these levels of care and the mental health workers who are authorized to administer 
these drugs (WHO, 2009). 
 
In spite of the incorporation of mental health services into the public health care system as well 
as standardized treatment procedures, South Africa still has a great challenge in the form of 
limited mental health human resources, low ranking of mental health as a public health priority, 
lack of infrastructure , the biomedical orientation of health care and poor information systems to 
monitor mental health service delivery which poses difficulties in the prescribing of these 
medicines as well (Lund et al, 2007). According to the South African Nursing Council and 
prescribing guidelines, primary health care nurses are not allowed to initiate prescriptions but 
they are allowed to continue prescriptions or they may also prescribe in emergency situations 
(WHO-AIMS, 2007). These nurses are not allowed to make any changes to prescriptions such 
as dose changes or change of the type of drugs, they are allowed to hand-out medicines and 
provide instructions on use if necessary. All types of doctors in the primary health care system 
are allowed to prescribe any of the medicines on the essential drug list (Department of health, 
2012). 
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Table 6.7.1: Distribution of health professionals. The estimated number of health professionals 
per 100 000 population shows the lack of available health professionals especially those in a 
specialized field 
 
Mental health professional Estimate of mental health professionals per 
100 000 population 
Psychiatric nurses  10.08 
Psychiatrists 0.28 
Other medical doctors (not specialized in 
psychiatry) 
0.45 
Psychologists 0.32 
Social workers 0.4 
Occupational therapists 0.13 
Other health or mental health workers 0.28 
 
Within the private health sector, the number of health professionals available is slightly better 
than that of the public health sector however, in a study investigating the use of SNRIs and 
SSRIs in patients younger than 19, general practitioners prescribed 67.76% of prescriptions 
while psychiatrists only prescribed 14.96% (Van Schalwyk and Truter, 2010) this shows that 
psychiatrists are consulted with less often than a general practitioner. This raises the question 
whether or not these patients have been adequately evaluated before commencing 
antidepressant therapy. This could possibly mean that the type of antidepressant chosen may 
not be suitable. Within this patient population, Venlafaxine had been prescribed to 6.32% of 
patients eventhough they are contraindicated in this patient population whilst Paroxetine had 
accounted for 5.96% of prescriptions though it is not recommended due to the possibility of 
suicidality side effects  (Van Schalwyk and Truter, 2010).  
 
A study using prescription data from a South African organization which evaluates the use of 
chronic medication for various medical aid companies had been done to show the prescribed 
daily dose of fluoxetine in 2117 patients in 1995 (Truter and Kotze, 1997). It showed that 86.5% 
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of females received a PDD of 20mg with 87.9% of males receiving the same PDD (Truter and 
Kotze, 1997). There had been a sudden increase in the use of fluoxetine in the age interval of 
30-40 years for females and in the age interval of 40-50 years for males; this shows that males 
generally used fluoxetine at a later stage in life compared to females (Truter and Kotze, 1997). 
 
In the U.S, a study using data from a Medical Expenditure Panel Survey database during the 
period of 2004-2007 had shown that a majority of patients were prescribed SSRI/SNRI 
antidepressants (71%) whereas only a small amount of patients had been prescribed the older 
generation TCAs (3%) (Lin et al, 2011).  
 
At the Charolotte Maxeke Johannesburg Academic Hospital (CMJAH) hospital however, 
prescribing is better due to the fact that it is a third degree referral centre which means that the 
staff is very well trained and available. Antidepressants were prescribed  
In the public sector, as mentioned previously, prescribing is done according to the Essential 
drug list (EDL) and the standard treatment guidelines (STGs). The WHO describes Essential 
medicines as those that satisfy the priority health care needs of the population. The list was 
designed for essential medicines to be available within the context of a functional health system 
at all times in adequate quantities, dosages and forms with adequate quality and at a price the 
community can afford (NDoH, 2012). In the South African public health sector, the prescribing of 
any drug is limited to the essential drug list. The purpose of designing the EDL was: 
• To ensure the availability and accessibility of essential medicines to all citizens. 
• To ensure the safety, efficacy and quality of drugs. 
• To ensure good prescribing and dispensing practices. 
• To promote the rational use of drugs by prescribers, dispensers and patients through provision 
of the necessary training, education and information. 
• To promote the concept of individual responsibility for health, preventive care and informed 
decision-making. 
  
 
 
For MDD, the EDL recommends TCAs in the form of amitriptyline or imipramine as the first line 
of therapy with a starting dose of 25mg per day with a maximum dose of 150mg or either of the 
SSRIs in the form of citalopram and fluoxetine. If a sedating antidepressant is required and a 
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TCA cannot be used, mianserin is to be prescribed (NDoH, 2012). In the current study, the only 
antidepressants prescribed were SSRIs and the SNRI venlafaxine. In contrast to the EDL and 
STG recommendations there had been no TCAs prescribed neither was mianserin used for any 
of the patients in the clinic. Venlafaxine was not mentioned in the EDL guidelines eventhough it 
was widely prescribed in this study. This shows that the actual prescribing patterns does differ 
from the STGs.   
 
6.7.1 Prescribing patterns with regard to diagnosis  
 
As expected, the diagnosis of a patient, which had been noted using the ICD 10 codes, had a 
great influence on the type of antidepressant chosen (p<0.0001). For patients with MDD, who 
represented more than half of the patient population, citalopram had been the most frequently 
prescribed antidepressant, accounting for 52.63% of prescriptions for patients with MDD 
followed by venlafaxine (32.90%) and then fluoxetine (14.47%). Amitriptyline had not been 
prescribed to any of the patients diagnosed with MDD. Patients who had been diagnosed as 
having MDD with feature of a generalized anxiety disorder had shown a similar pattern of 
prescribing with citalopram (55.56%) being the first choice followed by venlafaxine (27.78%), 
which is lower than the MDD group. In these patients, the percentage of those on fluoxetine 
(16.70%) had been slightly higher than patients who had been diagnosed as having solely 
MDD.  
 
In patients who had been diagnosed with MDD and psychosis, the pattern of diagnosing had 
deviated from the first 2 groups. Fluoxetine had been preferred among these patients to a 
greater extent than venlafaxine and citalopram. The second drug of choice for prescribers when 
treating these patients had shown to be venlafaxine with citalopram being the least preferred, in 
contrast to the patients with MDD alone and MDD with GAD who had received more citalopram 
than any other antidepressant. MDD with epilepsy had shown more patients receiving 
Citalopram, followed by fluoxetine and then venlafaxine. In bipolar mood disorder with MDD, 
once again citalopram had been prescribed more than any other antidepressant, with fluoxetine 
and venlafaxine being prescribed in equal amounts.  
In total, citalopram had been the most widely prescribed drug, accounting for 51.46% of all 
antidepressants. The second most widely prescribed was venlafaxine (30.33%) then fluoxetine 
(18.03%). This shows the way in which amitriptyline has been phased out from being used as 
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treatment for depression and is only used for pain management purposes. The study clearly 
demonstrates the way in which SSRIs such as citalopram and fluoxetine and the SNRI 
Venlafaxine have replaced the need for the use of older TCAs such as amitriptyline. The use of 
SSRIs had seen a 5.8-fold increase in use between 1991 and 2011 (Aarts et al, 2014). 
 
Although the potency of SSRIs are often debated upon when they are compared to TCAs and 
other older antidepressants, most psychiatrists and other health professionals agree that they 
should be used as the first choice of drugs because of their lower side effect profile. An older 
drug utilization review conducted in Denmark that approximately 75% of had TCAs prescribed to 
them, whilst SSRIs were only used by 10% of the population (Rosholm et al, 1993). This shows 
the way in which the use of antidepressants has changed over the years.  
 
This finding has been mirrored in other studies, one that had been conducted over various 
countries in Europe. It showed that the most commonly prescribed antidepressant had been an 
SSRI (63.30%) which is then followed by SNRIs (13.60%) (Bauer et al, 2008). The study 
confirms the increased use of SSRIs in the elderly and middle-aged population; this is most 
likely due to the low toxicity, mild adverse drug reaction profile and no need for plasma 
monitoring (Parabiaghi et al, 2011).  SSRIs prescribed ranged from 31.7% in Germany to 81.5% 
in France (Bauer et al, 2008). In Spain, the most frequently prescribed group of antidepressants 
were SSRIs at 68.80% followed by TCAs at 18.20% (Serna et al, 2010). In the US, the trend of 
TCA prescribing had been even less than that of the European counterparts. SSRI/SNRI type 
antidepressants were prescribed to 71% of the patients in contrast to the 3% of patients that 
were prescribed older antidepressants such as TCAs (Lin et al, 2011). 
In children and adolescents of all the antidepressants prescribed, only 41.72% were for SSRIs 
with a large number being for 33.99% of prescriptions in the German sample (Dorks et al, 
2013). Studies done in South Africa had shown a similar finding. In another study where a 
private medical scheme database had been used to investigate the SNRIs and SSRIs in the 
children and adolescent patient population, it had been shown that SSRIs and SNRIs were 
prescribed to 50.68% of these patients (Van Schalwyk and Truter, 2010). Comparing the use of 
specific SSRIs, in 1995 fluoxetine had been the most frequently prescribed SSRI accounting for 
63.3% of all the SSRIS followed by paroxetine accounting for 28.5% (Truter and Kotze, 1997). 
Surprisingly, citalopram accounted for only 9.2% of all the SSRIs prescribed and venlafaxine 
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only 0.5% (Truter and Kotze, 1997) perhaps because generic versions of these medicines were 
not available at that time. 
 
 
TCAs were prescribed for only 1.5% of patients in the Netherlands and 8.6% in Austria but 
accounted for 26.5% of antidepressants prescribed in Germany (Bauer et al, 2008). When a 
study with a greater time span is conducted to show the way in which antidepressants are 
prescribed, amitriptyline and paroxetine had been the most commonly prescribed 
antidepressant with mirtazapine and venlafaxine being the other antidepressants prescribed but 
to a lesser extent (Aarts et al, 2014). It is often found that amitriptyline is preferred for its other 
indications. If a study is done on a larger patient sample with a larger patient population and 
takes into account other types of diagnosis with the antidepressant being the predictor for a 
patient being chosen to be part of the sample, it can be shown that the prevalence of use on 
TCAs is relatively high. The high prevalence in the use of TCAs might be explained by the 
numerous indications for which these drugs are also prescribed; this includes neuropathic pain 
(Raymond et al, 2007). 
 
Of the total of 1606 prescriptions which had been the repeats for the 135 patients, 672 had been 
for citalopram, 560 had been made for venlafaxine, 259 for fluoxetine and 115 for amitriptyline. 
A study in Denmark showed that of all the antidepressants prescribed, to the patient population 
which consisted of over 25 000 patients, 71.53% had been an SSRI drug, 10.89% a TCA 
antidepressant and 5.32% an SNRI (Gasse et al, 2013).  
 
The SSRIs citalopram and fluoxetine had been prescribed more frequently than any other class 
of drug to these patients in this study. SNRIs in the form of venlafaxine followed secondly with 
the older generation TCAs no longer used in the treatment of depression; instead it is used for 
its other indications in pain management.  
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6.7.2 Diagnosis and patient factors 
 
One of the objectives of the study had been to determine if there are any patient factors such as 
gender, age, race, marital status or even employment status that may have an influence on the 
diagnosis of the patient. In order to determine if there is an association between these factors 
and the diagnosis, chi squared tests had been performed to create a probability value. Of all the 
patient factors, the race of a patient had been shown to have an influence on the diagnosis 
made by the health professional (p=0.008).  
There have been numerous studies that have been done in order to investigate the kinds of 
factors that affect the health professional’s decision in making a diagnosis and prescribing. 
Theoretical models have shown, through the examination of sociological influences, that the 
decision made by a health professional is influenced by four characteristics namely: the health 
professionals relationship with the patient, the health professionals relationship with the health 
care system (the setting of the practice), the characteristics of the health care professional such 
as age, specialty, race, gender, as well as the characteristics of the patient namely race, gender 
and age (Clark et al, 1991). There have been other studies which have re-iterated the findings 
of these papers (Bradley, 1991 and Gabe, 1990). 
 
6.8 Use of antidepressants  
 
Of the total of 1606 prescriptions which had been the repeats for the 135 patients, 672 had been 
for citalopram, 560 had been made for venlafaxine, 259 for fluoxetine and 115 for amitriptyline. 
A drug utilization research method that is used for the analysis of data is the Defined Daily Dose 
(DDD) method. DDD is known as the dose which corresponds to the average dose per day for a 
drug, when used for the main indication in adults (WHO, 2003). There are limitations to the use 
of the DDD because a large percentage of drugs are used for off –label indications, therefore 
are used at different dosages. The DDD is a technical unit of measurement, and is not 
necessarily equivalent to the average doses actually prescribed. Therefore, the prescribed daily 
dose (PDD) is used to overcome the limitations of the DDD. The PDD is the average of the 
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actual prescribed dose of the drug and is obtained the dosing instructions in prescriptions 
(Truter and Kotze, 1997). The PDD was calculated by multiplying the number of tablets 
dispensed during the period and the strength per tablet divided by the number of days supplied.  
In this study the PDD for fluoxetine was 35mg which is above the WHO DDD of 20mg. The PDD 
of citalopram was 29mg. Venlafaxine in this study had been prescribed at a PDD of 239mg 
which higher than the WHO DDD of 100mg. Changes in antidepressant type as well as stopped 
therapy as a result of review in therapy can sometimes cause a reduction in the PDD as shown. 
A New Zealand based study showed that the PDD calculated in that patient population for 
citalopram was between 24-28 mg between 1999 and 2005. The same study showed the PDD 
for fluoxetine ranged between 18mg and 25mg from 1997 to 2005 with the PDD peaking mid-
point then finally decreasing to the lowest PDD of 18mg. With regards to venlafaxine the PDD 
ranged from 113-205mg from between 1999 – 2004 (Ministry of Health, 2007). In one study the 
result of change of antidepressant which caused a 9.5% reduction in the mean PDD (Johnson 
et al, 2012). Using a  sample of 98 adolescents and young adults in South Africa, investigated 
the prescribing patterns of TCAs and SSRIs, investigators found that the SSRIs were more 
likely to be prescribed within a close range of the DDD than the TCAs (Kairuz et al, 2003). 
In this study, of the total patient population, almost half had been prescribed citalopram as their 
antidepressant (51.64%), followed by venlafaxine (30.33%) then fluoxetine (18.03%). The 
finding of the dominance of SSRIs has been mirrored in another study which showed that it 
been prescribed to 69.6% of participants with SNRIs contributing to 13.7% (Bukh et al, 2013). In 
South Africa, fluoxetine had been most commonly prescribed (36.5%), then citalopram (22.14%) 
followed by escitalopram (17.15%) (Van Schalwyk and Truter, 2010).  In the US, SSRI/SNRI 
type antidepressants were prescribed to 71% of the patients in contrast to the 3% of patients 
that were prescribed older antidepressants such as TCAs (Lin et al, 2011). The results of a 
study in Europe showed that the most commonly prescribed antidepressants were SSRIs 
(63.3% of all patients) which is then followed by SNRIs (13.6% of all patients) (Bauer et al, 
2008). The prescribing of different antidepressant groups varied between countries, this was 
shown as SSRIs prescribed ranged from 31.7% in Germany to 81.5% in France (Bauer et al, 
2008). 
 
These two antidepressants classes of SSRIs and TCAs accounted for 79.49% of the 
antidepressant cost (Truter, 2010). This type of practice is evident even though other studies 
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had shown that there had been a shift from the prescribing of TCAs to the better tolerated 
SSRIs (Guaiana et al, 2005; Lawrenson et al, 2000; Van Marwijk et al, 2001).  
 
The way in which the prescribing of SSRIs had come to dominate was shown in the study by the 
increase in the number of prescription from 1.0 million in 1991 to 20.8 million in 2005 (Chen et 
al, 2008). Of all the 16,886 antidepressants prescribed, 7,044 (41.72%) were SSRIs, 5,739 
(33.99%) were TCAs (Bauer et el, 2008). The number of prescriptions for TCAs increased 
steadily from 1991 in which it was 4.7 million to 6.4 million in 2001, it then showed a slight 
decrease in 2002 to 6.0 million but then proceeded to drastically decline to 3.7 million in 2005 
(Chen et al, 2008). In contrast, a study done from 2007-2011, amitriptyline and paroxetine were 
the most commonly prescribed antidepressants with mirtazapine and venlafaxine being the 
other antidepressants that were also commonly prescribed, but to a lesser extent (Aarts et al, 
2014). 
 
A study to show the prescribing patterns in patients younger than 18 years showed that SSRIs 
accounted for 55.91% of antidepressant prescriptions which was ahead only of TCAs which 
contributed to 32.32% of prescriptions. TCAs were prescribed for only 1.5% of patients in the 
Netherlands and 8.6% in Austria but accounted for 26.5% of antidepressants prescribed in 
Germany (Bauer et al, 2008). An older study that had been done using information from a 
medicines certification centre in 1995 showed that the most frequently prescribed 
antidepressant at that time had been TCAs accounting for 40.9% of all the antidepressants 
followed by SSRs which together accounted for a total of 75% of all antidepressants prescribed 
(Truter and Kotze, 1997). In patients over 55 years, the preferred antidepressants were 
amitriptyline and paroxetine (Aarts et al, 2014). 
 
One of the main aims of this study was to show what kind of patient factors had an influence on 
the type of antidepressant prescribed. In studies conducted internationally, the following patient 
factors have been found to have an influence on the type of antidepressant prescribed, female 
gender (Aparasu et al, 1998; Ganguli et al, 1997), white patients compared to non-white 
patients (Aparasu et al 1998; Wells et al, 1994), older age, higher education level and repeated 
visits to a psychiatrist (Well et al, 1994). 
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6.8.1 Repeated use of antidepressant types 
 
Based on the number of prescriptions for each antidepressant used and by the number of 
patients using each antidepressant, an average number of repeats had been calculated. The 
antidepressant with the most number of repeats was venlafaxine with an average of 15.13 
repeats followed by fluoxetine with 11.77 repeats and citalopram with 10.67 repeats. This shows 
that patients on venlafaxine had shown the greatest persistence in returning for their medicine, 
which could indicate better compliance. This could be attributed to the better side effect profile 
of the drug so perhaps that it was better tolerated in the patients who have used it. The 
medicine possession ratio (MPR) is one way of measuring compliance. One south African study 
showed that after the first 4 months, only 34% of the patients were compliant with statistical 
significance shown between compliance and the active ingredient (p<0.001) (Slabbert et al, 
2015). However, the MPR is not a clear indication that the patient is actually using the 
medication.  
 
One study  had found the types of drugs that are associated with better compliance, which were 
maprotiline (48.1%) followed by venlafaxine (35%), mirtazapine (29%), citalopram (29.6%), 
clomipramine (29.6%) and fluoxetine (26%) (Serna et al, 2010).  One South African study 
showed that patients receiving venlafaxine had the greatest compliance (Slabbert et al., 2015). 
The high number of average repeats could be an indication of good adherence to the treatment 
regimen with the number of repeats being higher than the expected averages of 
antidepressants. A study in Spain had showed that half of the patients had abandoned or 
finished off their treatment during the second and fourth month while only 25% of the patients 
continued treatment for longer than 11 months (Serna et al, 2010). One study has shown that 
28% to 40% of patients being treated for depression discontinued their medication causing 
significant increases in their health care expenditures owing to more complaints or 
hospitalization (Olfson et al, 2006). 
 Interestingly, half of the men had stopped their treatment after 2 months and half the women 
after 3 months. Compliance was found to be acceptable in only 22% of patients; there were 
differences in the duration of treatment between both males and females only in the first four 
months however, after the four months, these differences disappeared (Serna et al, 2010). Men 
are shown to be more likely to stop antidepressant therapy due to the sexual dysfunction 
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caused by the use of antidepressants (Segraves and Ballon, 2014). With regards to adherence 
it was shown that only 23% of patients in the study had highly adhered to their medications (Lin 
et al, 2011). One of the most important findings of this study was that only one out of five 
patients complied with treatment (duration of more than four months) with treatment periods 
being much shorter in males, 50% of which had abandoned treatment after two months (Serna 
et al, 2010). The therapy-related factors that can contribute to patient adherence include the 
number of medications, complexity of the treatment regimen, side effects, dosing frequency and 
the cost of treatment (Balkrishnan, 1998). In the current study it is unknown why the compliance 
was so good but, it is possible to speculate that the minimal cost of treatment coupled with 
professional patient management and short waiting times contribute to the persistence of patient 
with their treatment.  
 
 
6.9 Concomitant drug use 
 
Of all the drugs that had been prescribed with the antidepressants simultaneously, the most 
commonly prescribed of which had been Gabapentin and Clonazepam. Both of these are anti-
epileptic agents that can be used as mood stabilizers and anxiolytics respectively.  
 
The most commonly prescribed anti-psychotic drug had been risperidone. The use of 
antidepressants together with anti-psychotics has been widely documented; especially to note 
the efficacy of these drugs used together (Adams et al, 2013; Rief et al, 2016). One study 
showed that among all of the psychotropic drugs prescribed together with antidepressants, 
anxiolytics was prescribed to a greater extent than antipsychotics or hypnotics and sedatives 
(Cheung et al, 2015).  
 
Systemic antihistamines in the form of promethazine had also been prescribed to a number of 
patients. This antihistamine is sometimes used to treat insomnia or sleeplessness over a short 
period due to the highly sedative property of the drug (Rossiter et al, 2010). 
6.10 Costing 
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Depression is a disease of a chronic nature, there is an economic burden caused by depression 
not only in the direct cost involved in treating the condition in a continuous manner but also due 
to the indirect costs involved from a societal perspective. Depression adds to the economic 
burden as a result of its high prevalence, under-diagnosis and under-treatment (Ho et al, 2016). 
As a result of which the economic burden is increased due to possible hospitalization and days 
lost at work. The reasons why studies which measure the cost effectiveness of treatment have 
become vital within recent times is because of factors such as the increasing age of the 
population as well as limited economic growth and scarcity of resources which contributes to the 
importance of making more efficient use of resources that are available. By making use of such 
studies that measure the realistic cost of treating a depressed patients, health care providers 
are able to make better decisions that can benefit the patients as well as have economic 
advantages. 
 
Studies done in the US have estimated that the cost of dealing with depression had amounted 
to USD 43.7 billion in the year 1990, of these costs, 76% had been indirect costs which include 
items such as days of lost work production as well as negative impact on other medical 
conditions (Greenberg et al, 1999). A similar kind of study had been done in the UK at the same 
time period to assess the total cost of treating depression. This study had shown that the total 
cost of treating depression had been GBP 4.4 billion in England and Wales, with 86.70% of the 
cost being accounted for as indirect costs (Kind and Sorenson, 1993). When the same study 
had been conducted 10 years later in the year 2000, it had shown that the total cost had 
increased drastically to GBP 9 billion, 96% of which had been from indirect costs (Thomas and 
Morris, 2003). A US based study showed that economically, of the $8747 annually spent on all 
health care, $447 of which were spent on MDD-specific medication (Lin et al, 2011). 
 
 
In this study, the cost of treating each patient with antidepressants had been calculated by 
considering the patients dose and the cost per unit as shown on the public sector  database 
price list, according to the tender prices at which these drugs are acquired.  
The most expensive antidepressant used had been venlafaxine with a total cost of R5332.66 
per month to treat the 37 patients who had been prescribed that type of antidepressant. This 
has also been shown in other studies where the cost effectiveness of using the different types of 
antidepressants had been compared.  Patients who had received venlafaxine had a greater 
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return rate than the other antidepressants for repeats. The extent of which had been calculated 
to be up to 5 months more than the other antidepressants. The average cost of treating each of 
the 37 patients with venlafaxine R144.12 per month. This same type of pattern had been shown  
in international studies as well (Sado et al, 2009).  
Fluoxetine had been the cheapest antidepressant with only a small difference, of between 
R1.02 and R3.00, as compared to the slightly more expensive citalopram. The most commonly 
prescribed dose for both fluoxetine and citalopram had been the 20mg which costs R8.44 and 
R9.46 respectively. The total cost of using fluoxetine to treat the 22 patients had been R329.16, 
with an average cost of R14.96.   
As mentioned previously, citalopram had been prescribed to a greater number of patients than 
any other antidepressant. The total cost of using citalopram had been R865.59. The average 
cost of treating each patient using citalopram had been R13.74.   
Since the development and use of SSRIs, there has been many studies that have been done to 
compare the cost effectiveness of using SSRIs and TCAs, with the results often showing that 
SSRIs are more cost effective for the treatment of depression compared to the older generation 
TCAs  (NICE, 2004). A private medical scheme database showing prescribing in patients 18 
years and younger, the total cost of antidepressant prescribing was R1 581 480 for the year 
2009 with an average cost of R126, 02 per item (Truter, 2010). SSRIs and TCAs were most 
frequently prescribed and together accounted for 79.49% of the total cost (Truter, 2010). The 
highest cost was for SNRIs (R322.94 per product), selective mono-amine oxidase inhibitors 
(R177.20) and SSRIs (R155.52) (Truter, 2010). 
 
A study done in Japan to compare the cost of antidepressant therapy alone with a combination 
of cognitive behavioral therapy and antidepressants had shown that the cost of combination 
therapy was JPY 449 655 per patient per year whilst antidepressant therapy alone had been 
JPY 422 244 per patient for the year (Sado et al, 2009).   
It is clearly shown in this study that the use of SSRIs dominates above the use of other 
antidepressants. The main disadvantage of using SSRIs was that these drugs cost more 
compared to TCAs however, a study by Frank et al in 2001 show that although the cost of the 
drug itself is higher, the total cost of health care for a patient receiving SSRI therapy are the 
same or lower than the total health care cost of patients on other antidepressants.  
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The cost involved in the use of concomitant drugs had been calculated as a means to 
demonstrate the total cost of treating a single patient at the clinic. The cost of each of the 
concomitant drugs was shown in section 5.6. The cheapest drug used was the anti-psychotic 
risperidone, which resulted in a total cost of R291.94 for the 22 patients who had received 
treatment with the drug.  
 
An adequate amount of funds is made available to purchase the basic essential psychotropic 
drugs which are then distributed at different levels of health care which ensure that these drugs 
are available in all provinces by their respective governing bodies, according to the National 
Department of Health. This however, is not the case in reality in the public health sector with 
health professionals which shows that prescribing is limited according to what drugs the hospital 
is able to acquire; this is regulated by the availability of funds.  Depression thus represents an 
important health problem, which is associated not only with a reduction in patients ’quality of life, 
but also with a high social cost, directly, in terms of healthcare resource utilization, and 
indirectly, in terms of lost productivity. 
 
 
Figure 6.10.1:  the percentage of the health care budget shows that a large proportion is spent 
on other health care expenses (95%) and only a small portion (5%) is dedicated to mental 
health expenses (WHO-AIMS, 2007).  
% of expenditure towards mental health 
Mental health expenses
Other health expenses
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The total cost of mood disorders that includes depression in the European union have been 
estimated to stand at around €113.4 billion, half of which has been related to the direct cost of 
sick leave which accounts for a large percentage of this (Gustavsson et al, 2011). 
 
6.11 Change of antidepressant.  
 
Throughout the study, there had been only 2 patients who had their types of antidepressant 
changed. The first of which was a 62 year old Black female which had her antidepressant 
changed from 20mg of citalopram to an end dose of 225mg of venlafaxine. She had first been 
tapered down off the citalopram dosing by reducing the dose slowly in intervals of a week at a 
time from 20mg to 10mg. She had then been moved onto venlafaxine in which a similar 
procedure was used to slowly increase the dose from 37.5mg a day for one week to 75mg per 
day for one week gradually doubling the dose until the total dose of 225mg had been reached. 
In order to achieve this dose she had to take 1 of the 75mg capsules as well as 1 of the 150mg 
capsules. She had been on the Citalopram for two months before the antidepressant was 
changed to venlafaxine. 
The other patient was a 46 year old white female who had also been changed from fluoxetine to 
venlafaxine. She had also started on a low dose of fluoxetine of 20mg for a period of five 
months before she had been changed over to venlafaxine which was slowly increased weekly to 
reach an end dose of 150mg.  
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6.12 Limitations of the study 
 
This study could have been conducted on a larger patient population to achieve a result that 
would be of greater statistical significance. The sample size was calculated for number of 
prescriptions and not by number of patients. A greater number of patients could have been used 
from a number of psychiatric out-patient clinics in order to achieve a result which represents a 
greater variety of patients.  
This study had only considered antidepressants that are prescribed to treat psychiatric 
conditions. The off-label uses of these drugs therefore have not been included in this study 
which does not show the extent to which antidepressants are prescribed for other conditions. In 
addition, the use of antidepressants for other registered indications for example pain relief for 
diabetic neuropathy, was not considered in this study, since the study is restricted to the 
psychiatric out-patient clinic. 
 
Since this study was a retrospective review of records, only direct medication costs were 
calculated and indirect costs were not considered.  
 
Chapter Summary 
The results of this study were compared with the results of both international and local drug 
utilization reviews. As expected, there had been a number of similarities in the results but, there 
had been a number of differences as well.  
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Chapter  Seven: Conclusions and future studies 
 
 This study has shown the way in which the treatment of depression has shifted from TCAs, as 
shown in older drug utilization reviews, to the newer SSRIs and SNRIs. This could be attributed 
to the better safety profile which decreases the need for therapeutic monitoring and the 
introduction of generics for the SSRIs and SNRIs which contain costs.  
In this South African population, a majority of the prescriptions had been made to female 
patients. Depression is more prevalent in women however; this could also show that women 
seek treatment more frequently than men. The finding concurs with international studies which 
show that depression is more prevalent in women than men.  
Previous international studies have shown that the prevalence of depression varies among 
different race groups. Patient ethnicity was one of the factors which was considered an 
important epidemiological factor worth considering, the results of which has shown that the 
majority of which were patients of a Caucasian origin followed by Black, Indian and Coloured 
patients respectively. This patient factor has showed to have an association with the types of 
antidepressant prescribed.  
 
The average age of the patients had been within close range of those of other antidepressant 
drug utilization reviews. The employment statuses as well as the marital statuses had also been 
considered as a means to gather more information about the type of population to which 
antidepressants were prescribed. Unemployed patients had formed the majority of the 
population whilst a majority of the population is married. That finding brings into question some 
of the studies which have concluded that married individuals are shown to enjoy a longer and 
healthier life both mentally and physically.  
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Citalopram had been the most frequently prescribed antidepressant among the entire patient 
population. SSRIs and SNRIs were prescribed in accordance with EDL guidelines according to 
the diagnosis. The EDL guidelines were not followed with TCAs not being used at all with 
venlafaxine, a drug which had not being mentioned in the EDL and STGs list, being prescribed 
often at the treatment facility.   
 
Future studies can be done over a larger patient population in the public sector should be 
considered in order to provide more information on the prescribing patterns of antidepressants 
as well as the demographics of patients using these drugs.  
This study had not taken into account the off-label use of antidepressants due to the fact that it 
had only collected data from a specialized psychiatric clinic. In order to have clearer insight into 
the manner in which these drugs are prescribed in the public sector, more studies should be 
done on patients receiving antidepressants for other conditions such as neuropathic pain in 
diabetes.  
 
 
 
Chapter summary 
The findings of this study provides useful information on the use of antidepressants in this 
particular patient population. The small sample size could be a limitation of the study however, 
this leaves room for future studies in the public sector with a greater sample size. 
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Appendix C: Data variables coding 
Variable Type Number 
Sex Female 1 
  Male 2 
      
Race Black 1 
  White 2 
  Coloured 3 
  Indian 4 
      
Employment status Unemployed 1 
  Pensioner 2 
  Employed 3 
      
Marital status Married 1 
  Single 2 
  Divorced 3 
  Widowed 4 
      
ICD Code MDD 1 
  MDD.GAD 2 
  MDD.Psychosis 3 
  Mild Depression 4 
  MDD.Epilepsy 5 
  MDD.BPD 6 
  
       
Antidepressant Fluoxetine 1 
  Citalopram 2 
  Venlafaxine 3 
  Amitriptyline 4 
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Appendix D: ICD-10 codes with their definitions 
ICD-10 code Definition 
  
F32 Depressive disorder 
F32.0 Mild depressive episode 
F32.1 Moderate depressive episode 
F32.2 Severe depressive episode without  
Psychotic symptoms 
F32.3 Severe depressive episode with psychotic 
symptoms 
F32.8 Other depressive episodes 
F32.9 Depressive Episode, unspecified 
F33 Recurrent depressive disorder, current 
episode mild 
F33.1 Recurrent depressive disorder, current 
episode moderate 
F33.2 Recurrent depressive disorder, current 
episode severe with no psychotic symptoms 
F33.3 Recurrent depressive disorder, current 
episode sever with psychotic symptoms 
F33.4  Recurrent depressive disorder, currently in 
remission 
F33.8 Other recurrent depressive disorders 
F34 Persistent mood disorders 
F34.0  Cyclothymia 
F34.1 Dysthymia 
F40 Phobic disorders 
F40.0  Agoraphobia 
F40.1  Social Phobia 
F41.1 Generalized anxiety disorder 
F41.2 Mixed Anxiety and depressive disorder 
F42 Obsessive compulsive disorder 
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